

Ovarian cancer: identifying and managing familial and genetic risk

Supplement 2 - Economic literature

NICE guideline tbc

Supplement 2

September 2023

Draft for consultation

These supplements were developed by NICE

Disclaimer

The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or service users. The recommendations in this guideline are not mandatory and the guideline does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or their carer or guardian.

Local commissioners and/or providers have a responsibility to enable the guideline to be applied when individual health professionals and their patients or service users wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with compliance with those duties.

NICE guidelines cover health and care in England. Decisions on how they apply in other UK countries are made by ministers in the [Welsh Government](#), [Scottish Government](#), and [Northern Ireland Executive](#). All NICE guidance is subject to regular review and may be updated or withdrawn.

Copyright

© NICE, 2023. All rights reserved. Subject to [Notice of Rights](#).

ISBN:

Contents

Contents	4
Economic literature search strategies	5
Database: Ovid MEDLINE(R) ALL.....	5
Database: Embase	7
Database: CRD HTA	8
Database: INAHTA International HTA Database.....	10
Database: Ovid MEDLINE(R) ALL.....	11
Database: Embase	14
Database: INAHTA International HTA Database.....	17
Database: Ovid MEDLINE(R) ALL.....	18
Database: Embase	21
Database: INAHTA International HTA Database.....	23
Economic study selection	25
References to included economic studies.....	50

Economic literature search strategies

A single economic search was undertaken for all topics included in the scope of this guideline. Databases searched, and search strategies are summarised below.

Database: Ovid MEDLINE(R) ALL

Date of last search: 27/03/2023

#	Searches
1	exp Ovarian Neoplasms/
2	(ovar* adj5 (cancer* or neoplas* or carcino* or malignan* or tumo?*r* or adenocarcinoma* or sarcoma* or angiosarcoma* or lymphoma* or leiomyosarcoma* or metasta*)).tw,kf.
3	or/1-2
4	exp Breast Neoplasms/
5	exp "Neoplasms, Ductal, Lobular, and Medullary"/
6	((breast* or mammary) adj5 (cancer* or neoplas* or carcino* or malignan* or tumo?*r* or adenocarcinoma* or sarcoma* or angiosarcoma* or lymphoma* or leiomyosarcoma* or dcis or ductal or infiltrat* or intraductal* or lobular or medullary or metasta*)).tw,kf.
7	or/4-6
8	3 or 7
9	exp Genetic Predisposition to Disease/
10	Pedigree/
11	exp Neoplastic Syndromes, Hereditary/
12	((hereditary or inherit* or familial) adj3 (nonpolyposis or non polyposis) adj3 (colon or colorectal or bowel) adj3 (cancer* or neoplas* or carcino* or malignan* or tumo?*r* or adenocarcinoma* or sarcoma* or angiosarcoma* or lymphoma* or leiomyosarcoma* or metasta*)).tw,kf.
13	((lynch or Muir Torre) adj2 (syndrome* or cancer*)).tw,kf.
14	HNPCC.tw,kf.
15	(peutz* or intestin* polyposis or STK11 or LKB1 or PJS or hLKB1 or (perior* adj1 lentigino*)).tw,kf.
16	((hamartoma* or "polyps and spots" or cowden*) adj2 (syndrome* or polyp*)).tw,kf.
17	((hereditary or inherit* or familial or adenomato* or attenuated) adj3 polyp* adj3 (coli or colon or colorectal or bowel or rectum or intestin* or gastrointestin* or syndrome* or multiple)).tw,kf.
18	gardner* syndrome*.tw,kf.
19	(MUTYH or MYH or FAP or AFAP or APC).tw,kf.
20	((familial or inherit* or heredit* or predispos* or pre dispos* or susceptib* or ancestr* or genealog* or descent) adj2 (cancer* or neoplas* or carcino* or malignan* or tumo?*r* or adenocarcinoma* or sarcoma* or angiosarcoma* or lymphoma* or leiomyosarcoma* or metasta*)).tw,kf.
21	("hereditary breast and ovarian cancer" or HBOC or Li Fraumeni syndrome or SBLA or LFS).tw,kf.
22	(famil* adj2 histor* adj2 (cancer* or neoplas* or carcino* or malignan* or tumo?*r* or adenocarcinoma* or sarcoma* or angiosarcoma* or lymphoma* or leiomyosarcoma* or metasta*)).tw,kf.
23	risk factors/
24	((risk* or probabil*) adj3 (high* or increas* or factor* or rais*) adj3 (mutat* or malignan* or gene* or variant*)).tw,kf.
25	((carrier* or gene*) adj3 mutat*)).tw,kf.
26	exp Genes, Tumor Suppressor/
27	exp Tumor Suppressor Proteins/
28	((tumo?*r* or cancer* or metastas?s or growth*) adj2 (suppress* adj1 (gene* or protein*))).tw,kf.
29	(anti oncogene* or antioncogene* or onco suppressor* or oncosuppressor*).tw,kf.
30	exp Fanconi Anemia Complementation Group Proteins/
31	(Fanconi An?emia adj3 protein*).tw,kf.
32	(BRCA* or IRIS or PSCP or BRCC1 or BRIP1 or BACH1 or FANC* or PNCA* or RNF53 or PPP1R53 or FAD* or FACD or GLM3 or BRCC2 or XRCC11 or TP53 or P53 or PALB2 or RAD51* or R51H3 or BROVCA* or TRAD or BARD1 or MLH1 or MSH2 or MSH6 or PMS2).tw,kf.
33	("breast cancer gene 1" or "breast cancer gene 2").tw,kf.

#	Searches
34	Rad51 Recombinase/
35	Ataxia Telangiectasia Mutated Proteins/
36	((Ataxia telangiectasia adj1 mutated adj1 (protein* or kinase*)) or ATM or AT1 or ATA or ATC or ATD or ATDC or ATE or TEL1 or TELO1).tw,kf.
37	Checkpoint Kinase 2/
38	((((checkpoint or check point or serine threonine) adj2 (protein* or kinase*)) or CHEK2 or CDS1 or CHK2 or HuCds1 or LFS2 or PP1425 or RAD53 or hCds1 or hchk2).tw,kf.
39	Carcinoma, Small Cell/ge [Genetics]
40	(small cell adj2 (cancer* or carcinoma*) adj2 gene*).tw,kf.
41	(SMARCA4 or BRG1 or CSS4 or SNF2 or SWI2 or MRD16 or RPTSP2 or BAF190 or SNF2L4 or SNF2LB or hSNF2b or BAF190A or SNF2-beta).tw,kf.
42	exp Sertoli-Leydig Cell Tumor/
43	((Sertoli or leydig) adj3 (tumo?r* or adenoma* or cancer* or carcinoma* or neoplas* or metasta*)) or arrhenoblastoma* or andr?oblastoma* or SLCT or gynandroblastoma*).tw,kf.
44	(DICER?? or DCR1 or GLOW or MNG1 or aviD or HERNA or RMSE2 or K12H4?8-LIKE).tw,kf.
45	Epithelial Cell Adhesion Molecule/
46	Epithelial cell adhesion molecule*.tw,kf.
47	(EPCAM* or EP CAM or ESA or KSA or M4S1 or MK-1 or DIAR5 or EGP??? or Ly74 or gp40 or CD326 or GA733?? or GA 733 or KS1?4 or MIC18 or TROP1 or BerEp4 or HNPCC8 or LYNCH8 or MOC-31 or Ber-Ep4 or TACSTD1).tw,kf.
48	or/9-47
49	8 and 48
50	animals/ not humans/
51	exp Animals, Laboratory/
52	exp Animal Experimentation/
53	exp Models, Animal/
54	exp Rodentia/
55	(rat or rats or rodent* or mouse or mice).ti.
56	or/50-55
57	49 not 56
58	limit 57 to English language
59	Economics/
60	Value of life/
61	exp "Costs and Cost Analysis"/
62	exp Economics, Hospital/
63	exp Economics, Medical/
64	exp Resource Allocation/
65	Economics, Nursing/
66	Economics, Pharmaceutical/
67	exp "Fees and Charges"/
68	exp Budgets/
69	budget*.ti,ab.
70	cost*.ti,ab.
71	(economic* or pharmaco?economic*).ti,ab.
72	(price* or pricing*).ti,ab.
73	(financ* or fee or fees or expenditure* or saving*).ti,ab.
74	(value adj2 (money or monetary)).ti,ab.
75	resourc* allocat*.ti,ab.
76	(fund or funds or funding* or funded).ti,ab.
77	(ration or rations or rationing* or rationed).ti,ab.
78	ec.fs.
79	or/59-78
80	58 and 79

Database: Embase

Date of last search: 27/03/2023

#	Searches
1	exp ovary tumor/
2	(ovar* adj5 (cancer* or neoplas* or carcino* or malignan* or tumo?r* or adenocarcinoma* or sarcoma* or angiosarcoma* or lymphoma* or leiomyosarcoma* or metasta*)).tw,kf.
3	or/1-2
4	exp breast tumor/
5	((breast* or mammary) adj5 (cancer* or neoplas* or carcino* or malignan* or tumo?r* or adenocarcinoma* or sarcoma* or angiosarcoma* or lymphoma* or leiomyosarcoma* or dcis or ductal or infiltrat* or intraductal* or lobular or medullary or metasta*)).tw,kf.
6	or/4-5
7	3 or 6
8	exp genetic predisposition/
9	pedigree/
10	exp hereditary tumor syndrome/
11	((hereditary or inherit* or familial) adj3 (nonpolyposis or non polyposis) adj3 (colon or colorectal or bowel) adj3 (cancer* or neoplas* or carcino* or malignan* or tumo?r* or adenocarcinoma* or sarcoma* or angiosarcoma* or lymphoma* or leiomyosarcoma* or metasta*)).tw,kf.
12	((lynch or Muir Torre) adj2 (syndrome* or cancer*)).tw,kf.
13	HNPCC.tw,kf.
14	(peutz* or intestin* polyposis or STK11 or LKB1 or PJS or hLKB1 or (perior* adj1 lentigino*)).tw,kf.
15	((hamartoma* or "polyps and spots" or cowden*) adj2 (syndrome* or polyp*)).tw,kf.
16	((hereditary or inherit* or familial or adenomato* or attenuated) adj3 polyp* adj3 (coli or colon or colorectal or bowel or rectum or intestin* or gastrointestin* or syndrome* or multiple)).tw,kf.
17	gardner* syndrome*.tw,kf.
18	(MUTYH or MYH or FAP or AFAP or APC).tw,kf.
19	((familial or inherit* or heredit* or predispos* or pre dispos* or susceptib* or ancestr* or genealog* or descent) adj2 (cancer* or neoplas* or carcino* or malignan* or tumo?r* or adenocarcinoma* or sarcoma* or angiosarcoma* or lymphoma* or leiomyosarcoma* or metasta*)).tw,kf.
20	("hereditary breast and ovarian cancer" or HBOC or Li Fraumeni syndrome or SBLA or LFS).tw,kf.
21	(famil* adj2 histor* adj2 (cancer* or neoplas* or carcino* or malignan* or tumo?r* or adenocarcinoma* or sarcoma* or angiosarcoma* or lymphoma* or leiomyosarcoma* or metasta*)).tw,kf.
22	risk factor/
23	((risk* or probabil*) adj3 (high* or increas* or factor* or rais*) adj3 (mutat* or malignan* or gene* or variant*)).tw,kf.
24	((carrier* or gene*) adj3 mutat*).tw,kf.
25	tumor suppressor gene/
26	exp tumor suppressor protein/
27	((tumo?r* or cancer* or metastas?s or growth*) adj2 (suppress* adj1 (gene* or protein*))).tw,kf.
28	(anti oncogene* or antioncogene* or onco suppressor* or oncosuppressor*).tw,kf.
29	Fanconi anemia protein/
30	(Fanconi An?emia adj3 protein*).tw,kf.
31	(BRCA* or IRIS or PSCP or BRCC1 or BRIP1 or BACH1 or FANC* or PNCA* or RNF53 or PPP1R53 or FAD* or FACD or GLM3 or BRCC2 or XRCC11 or TP53 or P53 or PALB2 or RAD51* or R51H3 or BROVCA* or TRAD or BARD1 or MLH1 or MSH2 or MSH6 or PMS2).tw,kf.
32	("breast cancer gene 1" or "breast cancer gene 2").tw,kf.
33	Rad51 protein/
34	ATM protein/
35	((Ataxia telangiectasia adj1 mutated adj1 (protein* or kinase*)) or ATM or AT1 or ATA or ATC or ATD or ATDC or ATE or TEL1 or Telo1).tw,kf.
36	checkpoint kinase 2/
37	((checkpoint or check point or serine threonine) adj2 (protein* or kinase*)) or CHEK2 or CDS1 or CHK2 or HuCds1 or LFS2 or PP1425 or RAD53 or hCds1 or hchk2).tw,kf.
38	small cell carcinoma/
39	genetics/

#	Searches
40	38 and 39
41	(small cell adj2 (cancer* or carcinoma*) adj2 gene*).tw,kf.
42	(SMARCA4 or BRG1 or CSS4 or SNF2 or SWI2 or MRD16 or RTPS2 or BAF190 or SNF2L4 or SNF2LB or hSNF2b or BAF190A or SNF2-beta).tw,kf.
43	androblastoma/ or Sertoli cell tumor/ or Leydig cell tumor/
44	((Sertoli or leydig) adj3 (tumo?r* or adenoma* or cancer* or carcinoma* or neoplas* or metasta*)) or arrhenoblastoma* or andr?oblastoma* or SLCT or gynandroblastoma*).tw,kf.
45	(DICER?? or DCR1 or GLOW or MNG1 or aviD or HERNA or RMSE2 or K12H4?8-LIKE).tw,kf.
46	epithelial cell adhesion molecule/
47	Epithelial cell adhesion molecule*.tw,kf.
48	(EPCAM* or EP CAM or ESA or KSA or M4S1 or MK-1 or DIAR5 or EGP??? or Ly74 or gp40 or CD326 or GA733?? or GA 733 or KS1?4 or MIC18 or TROP1 or BerEp4 or HNPCC8 or LYNCH8 or MOC-31 or Ber-Ep4 or TACSTD1).tw,kf.
49	or/8-37,40-48
50	7 and 49
51	animal/ not human/
52	nonhuman/
53	exp Animal Experiment/
54	exp Experimental Animal/
55	animal model/
56	exp Rodent/
57	(rat or rats or rodent* or mouse or mice).ti.
58	or/51-57
59	50 not 58
60	(conference abstract* or conference review or conference paper or conference proceeding).db,pt,su.
61	59 not 60
62	limit 61 to English language
63	health economics/
64	exp economic evaluation/
65	exp health care cost/
66	exp fee/
67	budget/
68	funding/
69	budget*.ti,ab.
70	cost*.ti.
71	(economic* or pharmaco?economic*).ti.
72	(price* or pricing*).ti,ab.
73	(cost* adj2 (effective* or utilit* or benefit* or minimi* or unit* or estimat* or variable*)).ab.
74	(financ* or fee or fees).ti,ab.
75	(value adj2 (money or monetary)).ti,ab.
76	or/63-75
77	62 and 76

Database: CRD HTA

Date of last search: 27/03/2023

#	Searches
1	MeSH DESCRIPTOR Ovarian Neoplasms EXPLODE ALL TREES IN HTA
2	((ovar* NEAR5 (cancer* or neoplas* or carcino* or malignan* or tumo?r* or adenocarcinoma* or sarcoma* or angiosarcoma* or lymphoma* or leiomyosarcoma* or metasta*))) and (Project record:ZDT OR Full publication record:ZDT) IN HTA
3	#1 OR #2
4	MeSH DESCRIPTOR Breast Neoplasms EXPLODE ALL TREES IN HTA

#	Searches
5	MeSH DESCRIPTOR Neoplasms, Ductal, Lobular, and Medullary EXPLODE ALL TREES IN HTA
6	(((breast* or mammary) NEAR5 (cancer* or neoplas* or carcino* or malignan* or tumo?r* or adenocarcinoma* or sarcoma* or angiosarcoma* or lymphoma* or leiomyosarcoma* or dcis or ductal or infiltrat* or intraductal* or lobular or medullary or metasta*)))) and (Project record:ZDT OR Full publication record:ZDT) IN HTA
7	#4 OR #5 OR #6
8	#3 OR #7
9	MeSH DESCRIPTOR Pedigree IN HTA
10	MeSH DESCRIPTOR Neoplastic Syndromes, Hereditary EXPLODE ALL TREES IN HTA
11	(((hereditary or inherit* or familial) adj3 (nonpolyposis or non polyposis) NEAR3 (colon or colorectal or bowel) NEAR3 (cancer* or neoplas* or carcino* or malignan* or tumo?r* or adenocarcinoma* or sarcoma* or angiosarcoma* or lymphoma* or leiomyosarcoma* or metasta*)))) and (Project record:ZDT OR Full publication record:ZDT) IN HTA
12	(((lynch or Muir Torre) NEAR2 (syndrome* or cancer*)))) and (Project record:ZDT OR Full publication record:ZDT) IN HTA
13	((HNPCC)) and (Project record:ZDT OR Full publication record:ZDT) IN HTA
14	(((peutz* or intestin* polyposis or STK11 or LKB1 or PJS or hLKB1 or (perior* NEAR1 lentigino*)))) and (Project record:ZDT OR Full publication record:ZDT) IN HTA
15	(((hereditary or inherit* or familial or adenomato* or attenuated) NEAR3 polyp* NEAR3 (coli or colon or colorectal or bowel or rectum or intestin* or gastrointestin* or syndrome* or multiple)))) and (Project record:ZDT OR Full publication record:ZDT) IN HTA
16	((gardner* syndrome*)) and (Project record:ZDT OR Full publication record:ZDT) IN HTA
17	(((MUTYH or MYH or FAP or AFAP or APC))) and (Project record:ZDT OR Full publication record:ZDT) IN HTA
18	(((familial or inherit* or heredit* or predispos* or pre dispos* or susceptib* or ancestr* or genealog* or descent) NEAR2 (cancer* or neoplas* or carcino* or malignan* or tumo?r* or adenocarcinoma* or sarcoma* or angiosarcoma* or lymphoma* or leiomyosarcoma* or metasta*)))) and (Project record:ZDT OR Full publication record:ZDT) IN HTA
19	(((famil* NEAR2 histor* NEAR2 (cancer* or neoplas* or carcino* or malignan* or tumo?r* or adenocarcinoma* or sarcoma* or angiosarcoma* or lymphoma* or leiomyosarcoma* or metasta*)))) and (Project record:ZDT OR Full publication record:ZDT) IN HTA
20	MeSH DESCRIPTOR risk factors IN HTA
21	(((risk* or probabil*) NEAR3 (high* or increas* or factor* or rais*) NEAR3 (mutat* or malignan* or gene* or variant*)))) and (Project record:ZDT OR Full publication record:ZDT) IN HTA
22	(((carrier* or gene*) NEAR3 mutat*)) and (Project record:ZDT OR Full publication record:ZDT) IN HTA
23	MeSH DESCRIPTOR Genes, Tumor Suppressor EXPLODE ALL TREES IN HTA
24	MeSH DESCRIPTOR Tumor Suppressor Proteins EXPLODE ALL TREES IN HTA
25	(((tumo?r* or cancer* or metastas?s or growth*) NEAR2 (suppress* NEAR1 (gene* or protein*)))) and (Project record:ZDT OR Full publication record:ZDT) IN HTA
26	(((anti oncogene* or antioncogene* or onco suppressor* or oncosuppressor*))) and (Project record:ZDT OR Full publication record:ZDT) IN HTA
27	MeSH DESCRIPTOR Fanconi Anemia Complementation Group Proteins EXPLODE ALL TREES IN HTA
28	(((Fanconi An?emia NEAR3 protein*))) and (Project record:ZDT OR Full publication record:ZDT) IN HTA
29	(((BRCA* or IRIS or PSCP or BRCC1 or BRIP1 or BACH1 or FANC* or PNCA* or RNF53 or PPP1R53 or FAD* or FACD or GLM3 or BRCC2 or XRCC11 or TP53 or P53 or PALB2 or RAD51* or R51H3 or BROVCA* or TRAD or BARD1 or MLH1 or MSH2 or MSH6 or PMS2))) and (Project record:ZDT OR Full publication record:ZDT) IN HTA
30	(((breast cancer gene 1" or "breast cancer gene 2")))) and (Project record:ZDT OR Full publication record:ZDT) IN HTA
31	MeSH DESCRIPTOR Rad51 Recombinase IN HTA
32	MeSH DESCRIPTOR Ataxia Telangiectasia Mutated Proteins IN HTA
33	(((Ataxia telangiectasia NEAR1 mutated NEAR1 (protein* or kinase*) or ATM or AT1 or ATA or ATC or ATD or ATDC or ATE or TEL1 or TELO1))) and (Project record:ZDT OR Full publication record:ZDT) IN HTA
34	MeSH DESCRIPTOR Checkpoint Kinase 2 IN HTA
35	(((checkpoint or check point or serine threonine) NEAR2 (protein* or kinase*) or CHEK2 or CDS1 or CHK2 or HuCds1 or LFS2 or PP1425 or RAD53 or hCds1 or hchk2))) and (Project record:ZDT OR Full publication record:ZDT) IN HTA
36	MeSH DESCRIPTOR Carcinoma, Small Cell IN HTA
37	(((small cell NEAR2 (cancer* or carcinoma*) NEAR2 gene*))) and (Project record:ZDT OR Full publication record:ZDT) IN HTA
38	(((SMARCA4 or BRG1 or CSS4 or SNF2 or SWI2 or MRD16 or RTPS2 or BAF190 or SNF2L4 or SNF2LB or hSNF2b or BAF190A or SNF2-beta))) and (Project record:ZDT OR Full publication record:ZDT) IN HTA
39	MeSH DESCRIPTOR Sertoli-Leydig Cell Tumor EXPLODE ALL TREES IN HTA

#	Searches
40	(((((Sertoli or leydig) NEAR3 (tumo?* or adenoma* or cancer* or carcinoma* or neoplas* or metasta*)) or arrhenoblastoma* or andr?oblastoma* or SLCT or gynandroblastoma*))) and (Project record:ZDT OR Full publication record:ZDT) IN HTA
41	((DICER?? or DCR1 or GLOW or MNG1 or aviD or HERNA or RMSE2 or K12H4?8-LIKE))) and (Project record:ZDT OR Full publication record:ZDT) IN HTA
42	MeSH DESCRIPTOR Epithelial Cell Adhesion Molecule IN HTA
43	((Epithelial cell adhesion molecule*)) and (Project record:ZDT OR Full publication record:ZDT) IN HTA
44	((EPCAM* or EP CAM or ESA or KSA or M4S1 or MK-1 or DIAR5 or EGP??? or Ly74 or gp40 or CD326 or GA733?? or GA 733 or KS1?4 or MIC18 or TROP1 or BerEp4 or HNPCC8 or LYNCH8 or MOC-31 or Ber-Ep4 or TACSTD1))) and (Project record:ZDT OR Full publication record:ZDT) IN HTA
45	#9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26 OR #27 OR #28 OR #29 OR #30 OR #31 OR #32 OR #33 OR #34 OR #35 OR #36 OR #37 OR #38 OR #39 OR #40 OR #41 OR #42 OR #43 OR #44
46	#8 AND #45

Database: INAHTA International HTA Database

Date of last search: 27/03/2023

#	Searches
18	#17 AND #8
17	#16 OR #15 OR #14 OR #13 OR #12 OR #11 OR #10 OR #9
16	((BRCA* or IRIS or PSCP or BRCC1 or BRIP1 or BACH1 or FANC* or PNCA* or RNF53 or PPP1R53 or FAD* or FADC or GLM3 or BRCC2 or XRCC11 or TP53 or P53 or PALB2 or RAD51* or R51H3 or BROVCA* or TRAD or BARD1 or MLH1 or MSH2 or MSH6 or PMS2 or DICER1 or SMARCA4 or STK11 or LKB1 or PJS or hLKB1 or ATM or AT1 or ATA or ATC or ATD or ATDC or ATE or TEL1 or TELO1 or CHEK2 or CDS1 or CHK2 or HuCds1 or LFS2 or PP1425 or RAD53 or hCds1 or hchk2 or MUTYH or MYH or FAP or AFAP or APC))[Title] OR ((BRCA* or IRIS or PSCP or BRCC1 or BRIP1 or BACH1 or FANC* or PNCA* or RNF53 or PPP1R53 or FAD* or FADC or GLM3 or BRCC2 or XRCC11 or TP53 or P53 or PALB2 or RAD51* or R51H3 or BROVCA* or TRAD or BARD1 or MLH1 or MSH2 or MSH6 or PMS2 or DICER1 or SMARCA4 or STK11 or LKB1 or PJS or hLKB1 or ATM or AT1 or ATA or ATC or ATD or ATDC or ATE or TEL1 or TELO1 or CHEK2 or CDS1 or CHK2 or HuCds1 or LFS2 or PP1425 or RAD53 or hCds1 or hchk2 or MUTYH or MYH or FAP or AFAP or APC))[Title] OR ((BRCA* or IRIS or PSCP or BRCC1 or BRIP1 or BACH1 or FANC* or PNCA* or RNF53 or PPP1R53 or FAD* or FADC or GLM3 or BRCC2 or XRCC11 or TP53 or P53 or PALB2 or RAD51* or R51H3 or BROVCA* or TRAD or BARD1 or MLH1 or MSH2 or MSH6 or PMS2 or DICER1 or SMARCA4 or STK11 or LKB1 or PJS or hLKB1 or ATM or AT1 or ATA or ATC or ATD or ATDC or ATE or TEL1 or TELO1 or CHEK2 or CDS1 or CHK2 or HuCds1 or LFS2 or PP1425 or RAD53 or hCds1 or hchk2 or MUTYH or MYH or FAP or AFAP or APC))[Title] OR ((BRCA* or IRIS or PSCP or BRCC1 or BRIP1 or BACH1 or FANC* or PNCA* or RNF53 or PPP1R53 or FAD* or FADC or GLM3 or BRCC2 or XRCC11 or TP53 or P53 or PALB2 or RAD51* or R51H3 or BROVCA* or TRAD or BARD1 or MLH1 or MSH2 or MSH6 or PMS2 or DICER1 or SMARCA4 or STK11 or LKB1 or PJS or hLKB1 or ATM or AT1 or ATA or ATC or ATD or ATDC or ATE or TEL1 or TELO1 or CHEK2 or CDS1 or CHK2 or HuCds1 or LFS2 or PP1425 or RAD53 or hCds1 or hchk2 or MUTYH or MYH or FAP or AFAP or APC))[abs]
15	((carrier* or gene*) AND mutat*))[Title] OR ((carrier* or gene*) AND mutat*))[abs]
14	(("hereditary breast and ovarian cancer" or HBOC or "Li Fraumeni syndrome" or SBLA or LFS))[Title] OR ((hereditary breast and ovarian cancer" or HBOC or "Li Fraumeni syndrome" or SBLA or LFS))[abs]
13	((familial or inherit* or heredit* or predispos* or pre dispos* or susceptib*) AND (cancer* or neoplas* or carcino* or malignan* or tumo?* or adenocarcinoma* or sarcoma* or angiosarcoma* or lymphoma* or leiomyosarcoma* or metasta*)))[Title] OR (((familial or inherit* or heredit* or predispos* or pre dispos* or susceptib*) AND (cancer* or neoplas* or carcino* or malignan* or tumo?* or adenocarcinoma* or sarcoma* or angiosarcoma* or lymphoma* or leiomyosarcoma* or metasta*)))[abs]
12	((MUTYH or MYH or FAP or AFAP or APC))[Title] OR ((MUTYH or MYH or FAP or AFAP or APC))[abs]
11	((hereditary or inherit* or familial or adenomato* or attenuated) AND polyp* AND (coli or colon or colorectal or bowel or rectum or intestin* or gastrointestin* or syndrome* or multiple)))[Title] OR (((hereditary or inherit* or familial or adenomato* or attenuated) AND polyp* AND (coli or colon or colorectal or bowel or rectum or intestin* or gastrointestin* or syndrome* or multiple)))[abs]
10	((peutz* or intestin* polyposis or STK11 or LKB1 or PJS or hLKB1))[Title] OR ((peutz* or intestin* polyposis or STK11 or LKB1 or PJS or hLKB1))[abs]
9	((hereditary or inherit* or familial) AND (nonpolyposis or non polyposis) AND (colon or colorectal or bowel) AND cancer*)))[Title] OR (((hereditary or inherit* or familial) AND (nonpolyposis or non polyposis) AND (colon or colorectal or bowel) AND cancer*)))[abs]
8	#7 OR #3
7	#6 OR #5 OR #4
6	((breast* or mammary) AND (cancer* or neoplas* or carcino* or malignan* or tumo?* or adenocarcinoma* or sarcoma* or angiosarcoma* or lymphoma* or leiomyosarcoma* or dcis or ductal or infiltrat* or intraductal* or lobular or

#	Searches
	medullary or metasta*))][Title] OR (((breast* or mammary) AND (cancer* or neoplas* or carcino* or malignan* or tumo?r* or adenocarcinoma* or sarcoma* or angiosarcoma* or lymphoma* or leiomyosarcoma* or dcis or ductal or infiltrat* or intraductal* or lobular or medullary or metasta*)))[abs]
5	"Neoplasms, Ductal, Lobular, and Medullary"[mh]
4	"Breast Neoplasms"[mhe]
3	#2 OR #1
2	((ovar* AND (cancer* or neoplas* or carcino* or malignan* or tumo?r* or adenocarcinoma* or sarcoma* or angiosarcoma* or lymphoma* or leiomyosarcoma* or metasta*)))[Title] OR ((ovar* AND (cancer* or neoplas* or carcino* or malignan* or tumo?r* or adenocarcinoma* or sarcoma* or angiosarcoma* or lymphoma* or leiomyosarcoma* or metasta*)))[abs]
1	"Ovarian Neoplasms"[mhe]

Search strategies for the update searches run for the following specific questions:

[E] What are the optimal methods of assessing the absolute risk of ovarian cancer in women with (or at an increased risk of) a pathogenic variant associated with familial ovarian cancer?

Database: Ovid MEDLINE(R) ALL

Date of last search: 27/03/2023

#	Searches
1	exp Ovarian Neoplasms/
2	(ovar* adj5 (cancer* or neoplas* or carcino* or malignan* or tumo?r* or adenocarcinoma* or sarcoma* or angiosarcoma* or lymphoma* or leiomyosarcoma* or metasta*).tw,kf.
3	or/1-2
4	exp Breast Neoplasms/
5	exp "Neoplasms, Ductal, Lobular, and Medullary"/
6	((breast* or mammary) adj5 (cancer* or neoplas* or carcino* or malignan* or tumo?r* or adenocarcinoma* or sarcoma* or angiosarcoma* or lymphoma* or leiomyosarcoma* or dcis or ductal or infiltrat* or intraductal* or lobular or medullary or metasta*).tw,kf.
7	or/4-6
8	3 or 7
9	exp Genetic Predisposition to Disease/
10	Pedigree/
11	exp Neoplastic Syndromes, Hereditary/
12	((hereditary or inherit* or familial) adj3 (nonpolyposis or non polyposis) adj3 (colon or colorectal or bowel) adj3 (cancer* or neoplas* or carcino* or malignan* or tumo?r* or adenocarcinoma* or sarcoma* or angiosarcoma* or lymphoma* or leiomyosarcoma* or metasta*).tw,kf.
13	((Lynch or Muir Torre) adj2 (syndrome* or cancer*).tw,kf.
14	HNPCC.tw,kf.
15	(peutz* or intestin* polyposis or STK11 or LKB1 or PJS or hLKB1 or (perior* adj1 lentigino*).tw,kf.
16	((hamartoma* or "polyps and spots" or cowden*) adj2 (syndrome* or polyp*).tw,kf.
17	((hereditary or inherit* or familial or adenomato* or attenuated) adj3 polyp* adj3 (coli or colon or colorectal or bowel or rectum or intestin* or gastrointestin* or syndrome* or multiple).tw,kf.
18	gardner* syndrome*.tw,kf.
19	(MUTYH or MYH or FAP or AFAP or APC).tw,kf.
20	((familial or inherit* or heredit* or predispos* or pre dispos* or susceptib* or ancestr* or genealog* or descent) adj2 (cancer* or neoplas* or carcino* or malignan* or tumo?r* or adenocarcinoma* or sarcoma* or angiosarcoma* or lymphoma* or leiomyosarcoma* or metasta*).tw,kf.
21	("hereditary breast and ovarian cancer" or HBOC or Li Fraumeni syndrome or SBLA or LFS).tw,kf.
22	(famil* adj2 histor* adj2 (cancer* or neoplas* or carcino* or malignan* or tumo?r* or adenocarcinoma* or sarcoma* or angiosarcoma* or lymphoma* or leiomyosarcoma* or metasta*).tw,kf.
23	risk factors/
24	((risk* or probabil*) adj3 (high* or increas* or factor* or rais*) adj3 (mutat* or malignan* or gene* or variant*).tw,kf.

Ovarian cancer: identifying and managing familial and genetic risk, Supplement 2 – Economic literature DRAFT for Consultation (September 2023)

#	Searches
25	((carrier* or gene*) adj3 mutat*).tw,kf.
26	exp Genes, Tumor Suppressor/
27	exp Tumor Suppressor Proteins/
28	((tumo?* or cancer* or metastas?s or growth*) adj2 (suppress* adj1 (gene* or protein*))).tw,kf.
29	(anti oncogene* or antioncogene* or onco suppressor* or oncosuppressor*).tw,kf.
30	exp Fanconi Anemia Complementation Group Proteins/
31	(Fanconi An?emia adj3 protein*).tw,kf.
32	(BRCA* or IRIS or PSCP or BRCC1 or BRIP1 or BACH1 or FANC* or PNCA* or RNF53 or PPP1R53 or FAD* or FACD or GLM3 or BRCC2 or XRCC11 or TP53 or P53 or PALB2 or RAD51* or R51H3 or BROVCA* or TRAD or BARD1 or MLH1 or MSH2 or MSH6 or PMS2).tw,kf.
33	("breast cancer gene 1" or "breast cancer gene 2").tw,kf.
34	Rad51 Recombinase/
35	Ataxia Telangiectasia Mutated Proteins/
36	((Ataxia telangiectasia adj1 mutated adj1 (protein* or kinase*)) or ATM or AT1 or ATA or ATC or ATD or ATDC or ATE or TEL1 or TELO1).tw,kf.
37	Checkpoint Kinase 2/
38	((((checkpoint or check point or serine threonine) adj2 (protein* or kinase*)) or CHEK2 or CDS1 or CHK2 or HuCds1 or LFS2 or PP1425 or RAD53 or hCds1 or hchk2).tw,kf.
39	Carcinoma, Small Cell/ge [Genetics]
40	(small cell adj2 (cancer* or carcinoma*) adj2 gene*).tw,kf.
41	(SMARCA4 or BRG1 or CSS4 or SNF2 or SWI2 or MRD16 or RTPS2 or BAF190 or SNF2L4 or SNF2LB or hSNF2b or BAF190A or SNF2-beta).tw,kf.
42	exp Sertoli-Leydig Cell Tumor/
43	((Sertoli or leydig) adj3 (tumo?* or adenoma* or cancer* or carcinoma* or neoplas* or metasta*) or arrhenoblastoma* or andr?oblastoma* or SLCT or gynandroblastoma*).tw,kf.
44	(DICER?? or DCR1 or GLOW or MNG1 or aviD or HERNA or RMSE2 or K12H4?8-LIKE).tw,kf.
45	Epithelial Cell Adhesion Molecule/
46	Epithelial cell adhesion molecule*.tw,kf.
47	(EPCAM* or EP CAM or ESA or KSA or M4S1 or MK-1 or DIAR5 or EGP??? or Ly74 or gp40 or CD326 or GA733?? or GA 733 or KS1?4 or MIC18 or TROP1 or BerEp4 or HNPCC8 or LYNCH8 or MOC-31 or Ber-Ep4 or TACSTD1).tw,kf.
48	or/9-47
49	8 and 48
50	(CANRISK or (cancer risk adj1 (tool or model*))).ti,ab,kf.
51	Multifactorial Inheritance/
52	((multifactor* or polygenic or polygene* or multigenic or oligogenic) adj2 (inherit* or trait* or character* or disease*)).ti,ab,kf.
53	((complex or heterogene*) adj2 (inherit* or trait*)).ti,ab,kf.
54	((polygenic or polygenetic or genome-wide) adj2 (score or risk or index or indices or study or studies)).ti,ab,kf.
55	Epigenesis, Genetic/
56	(epigene* adj2 (process* or change* or modif* or program* or misprogram*)).ti,ab,kf.
57	Age Factors/ or age groups/ or Life Style/ or Body Height/
58	((age? or birth cohort* or lifestyle or life style or "way* adj1 life" or height or stature) adj2 (cancer* or neoplas* or carcino* or malignan* or tumo?* or adenocarcinoma* or sarcoma* or angiosarcoma* or lymphoma* or leiomyosarcoma* or metasta* or risk*)).ti,ab,kf.
59	((lifetime or life time or personal*) adj1 risk).ti,ab.
60	((personal* or lifestyle or life style) adj2 (information or survey* or question*)).ti,ab,kf.
61	body mass index/ or body size/ or body weight/ or Body Composition/ or weight gain/ or overweight/
62	((((body adj2 (mass or weight or size or fat or fatness or composition)) or BMI or quetelet index or skin fold* or skinfold* or (weight adj2 (manag* or gain* or increas* or excess or chang*)) or (fat adj3 (percent* or distribution))) adj2 (cancer* or neoplas* or carcino* or malignan* or tumo?* or adenocarcinoma* or sarcoma* or angiosarcoma* or lymphoma* or leiomyosarcoma* or metasta* or risk*)).ti,ab,kf.
63	Alcohol Drinking/ or Smoking/ or Smokers/ or "Tobacco Use"/
64	((alcohol* adj2 (drink* or imbib* or intake or consumption or consum* or binge or abus* or frequenc* or behavio*r* or use* or using or problem*)) or smoking or smoke* or tobacco* or nicotin* or cigar* or cigs or ecig* or e-cig or e-

#	Searches
	voke* or vape* or vaping) adj2 (cancer* or neoplas* or carcino* or malignan* or tumo?* or adenocarcinoma* or sarcoma* or angiosarcoma* or lymphoma* or leiomyosarcoma* or metasta* or risk*).ti,ab,kf.
65	Parity/ or reproductive history/ or puberty/ or menarche/ or Menopause/
66	((parity or nullipar* or primipar* or primip or multipar* or para or offspring or menarche or menstrua* or menses or menorrhoea or pubert* or menopaus* or perimenopaus* or peri menopaus* or postmenopaus* or post menopaus* or POF or ((reproductive or birth* or pregnanc*) adj2 (histor* or factor*))) adj2 (cancer* or neoplas* or carcino* or malignan* or tumo?* or adenocarcinoma* or sarcoma* or angiosarcoma* or lymphoma* or leiomyosarcoma* or metasta* or risk*).ti,ab,kf.
67	Hormone Replacement Therapy/ or ESTROGENS/ or ESTRADIOL/ or contraceptive agents, female/ or contraceptives, oral/ or hormonal contraception/ or ovulation inhibition/
68	((((hormon* adj3 (therap* or substitut* or replacement or exogenous)) or ((oestrogen* or estrogen* or oestradiol or estradiol or estrone or oestrone or progest* or medroxyprogest*) adj3 (therap* or substitut* or replacement or exogenous))) adj2 (cancer* or neoplas* or carcino* or malignan* or tumo?* or adenocarcinoma* or sarcoma* or angiosarcoma* or lymphoma* or leiomyosarcoma* or metasta* or risk*).ti,ab,kf.
69	(HRT or HT or MHT).ti,ab,kf.
70	(((((oral or hormon*) adj3 contracept*) or (ovulat* adj2 (inhibit* or suppress* or block*))) adj2 (cancer* or neoplas* or carcino* or malignan* or tumo?* or adenocarcinoma* or sarcoma* or angiosarcoma* or lymphoma* or leiomyosarcoma* or metasta* or risk*).ti,ab,kf.
71	birth control pill*.ti,ab,kf.
72	Endometriosis/ or Adenomyosis/
73	((endometriosis or endometrioma* or adenomyosis or adenomyoma* or adenometritis or adenomyositis or adenomyometritis) adj2 (cancer* or neoplas* or carcino* or malignan* or tumo?* or adenocarcinoma* or sarcoma* or angiosarcoma* or lymphoma* or leiomyosarcoma* or metasta* or risk*).ti,ab,kf.
74	Population Groups/ or Demography/ or "Emigration and Immigration"/
75	exp "health disparity, minority and vulnerable populations"/
76	((ethnic* or nation* or race or racial or minority or minorities or indigenous or demograph* or population or ((countr* or place) adj3 (birth or born or origin*))) adj4 (cancer* or neoplas* or carcino* or malignan* or tumo?* or adenocarcinoma* or sarcoma* or angiosarcoma* or lymphoma* or leiomyosarcoma* or metasta* or risk*).ti,ab,kf.
77	((family or personal) adj2 history).ti,ab,kf.
78	((genetic or environment* or epidemiolog* or hormonal) adj2 risk*).ti,ab,kf.
79	or/50-78
80	exp Mass Screening/
81	((screen* or detect* or test* or diagnos*) adj2 (cancer* or neoplas* or carcino* or malignan* or tumo?* or adenocarcinoma* or sarcoma* or angiosarcoma* or lymphoma* or leiomyosarcoma* or metasta* or risk*).ti,ab,kf.
82	exp Early Diagnosis/
83	(early adj2 (diagnos* or detect* or identif*) adj3 (cancer* or neoplas* or carcino* or malignan* or tumo?* or adenocarcinoma* or sarcoma* or angiosarcoma* or lymphoma* or leiomyosarcoma* or metasta* or risk*).ti,ab,kf.
84	((assess* or probability or predict* or scor*) adj3 (tool* or model* or system* or test* or threshold*).ti,ab,kf.
85	risk/ or Epidemiology/
86	(risk adj3 (tool* or assess* or interval* or analys* or estimat* or predict* or factor* or model* or scor* or stratif* or test* or evaluat* or accuracy or accurate or epidemiolog*).ti,ab,kf.
87	or/80-86
88	79 and 87
89	49 and 88
90	letter/
91	editorial/
92	news/
93	exp historical article/
94	Anecdotes as Topic/
95	comment/
96	case reports/
97	(letter or comment*).ti.
98	animals/ not humans/
99	exp Animals, Laboratory/
100	exp Animal Experimentation/
101	exp Models, Animal/
102	exp Rodentia/

#	Searches
103	(rat or rats or mouse or mice or rodent*).ti.
104	or/90-103
105	89 not 104
106	limit 105 to English language
107	Economics/
108	Value of life/
109	exp "Costs and Cost Analysis"/
110	exp Economics, Hospital/
111	exp Economics, Medical/
112	exp Resource Allocation/
113	Economics, Nursing/
114	Economics, Pharmaceutical/
115	exp "Fees and Charges"/
116	exp Budgets/
117	budget*.ti,ab.
118	cost*.ti,ab.
119	(economic* or pharmaco?economic*).ti,ab.
120	(price* or pricing*).ti,ab.
121	(financ* or fee or fees or expenditure* or saving*).ti,ab.
122	(value adj2 (money or monetary)).ti,ab.
123	resourc* allocat*.ti,ab.
124	(fund or funds or funding* or funded).ti,ab.
125	(ration or rations or rationing* or rationed).ti,ab.
126	ec.fs.
127	or/107-126
128	106 and 127

Database: Embase

Date of last search: 27/03/2023

#	Searches
1	exp ovary tumor/
2	(ovar* adj5 (cancer* or neoplas* or carcino* or malignan* or tumo?*r* or adenocarcinoma* or sarcoma* or angiosarcoma* or lymphoma* or leiomyosarcoma* or metasta*)).tw,kf.
3	or/1-2
4	exp breast tumor/
5	((breast* or mammary) adj5 (cancer* or neoplas* or carcino* or malignan* or tumo?*r* or adenocarcinoma* or sarcoma* or angiosarcoma* or lymphoma* or leiomyosarcoma* or dcis or ductal or infiltrat* or intraductal* or lobular or medullary or metasta*)).tw,kf.
6	or/4-5
7	3 or 6
8	exp genetic predisposition/
9	pedigree/
10	exp hereditary tumor syndrome/
11	((hereditary or inherit* or familial) adj3 (nonpolyposis or non polyposis) adj3 (colon or colorectal or bowel) adj3 (cancer* or neoplas* or carcino* or malignan* or tumo?*r* or adenocarcinoma* or sarcoma* or angiosarcoma* or lymphoma* or leiomyosarcoma* or metasta*)).tw,kf.
12	((lynch or Muir Torre) adj2 (syndrome* or cancer*)).tw,kf.
13	HNPCC.tw,kf.
14	(peutz* or intestin* polyposis or STK11 or LKB1 or PJS or hLKB1 or (perior* adj1 lentigino*)).tw,kf.
15	((hamartoma* or "polyps and spots" or cowden*) adj2 (syndrome* or polyp*)).tw,kf.
16	((hereditary or inherit* or familial or adenomato* or attenuated) adj3 polyp* adj3 (coli or colon or colorectal or bowel or rectum or intestin* or gastrointestinal* or syndrome* or multiple)).tw,kf.

Ovarian cancer: identifying and managing familial and genetic risk, Supplement 2 –
 Economic literature DRAFT for Consultation (September 2023)

#	Searches
17	gardner* syndrome*.tw,kf.
18	(MUTYH or MYH or FAP or AFAP or APC).tw,kf.
19	((familial or inherit* or heredit* or predispos* or pre dispos* or susceptib* or ancestr* or genealog* or descent) adj2 (cancer* or neoplas* or carcino* or malignan* or tumo?* or adenocarcinoma* or sarcoma* or angiosarcoma* or lymphoma* or leiomyosarcoma* or metasta*).tw,kf.
20	("hereditary breast and ovarian cancer" or HBOC or Li Fraumeni syndrome or SBLA or LFS).tw,kf.
21	(famil* adj2 histor* adj2 (cancer* or neoplas* or carcino* or malignan* or tumo?* or adenocarcinoma* or sarcoma* or angiosarcoma* or lymphoma* or leiomyosarcoma* or metasta*).tw,kf.
22	risk factor/
23	((risk* or probabil*) adj3 (high* or increas* or factor* or rais*) adj3 (mutat* or malignan* or gene* or variant*).tw,kf.
24	((carrier* or gene*) adj3 mutat*).tw,kf.
25	tumor suppressor gene/
26	exp tumor suppressor protein/
27	((tumo?* or cancer* or metastas?s or growth*) adj2 (suppress* adj1 (gene* or protein*))).tw,kf.
28	(anti oncogene* or antioncogene* or onco suppressor* or oncosuppressor*).tw,kf.
29	Fanconi anemia protein/
30	(Fanconi An?emia adj3 protein*).tw,kf.
31	(BRCA* or IRIS or PSCP or BRCC1 or BRIP1 or BACH1 or FANC* or PNCA* or RNF53 or PPP1R53 or FAD* or FACD or GLM3 or BRCC2 or XRCC11 or TP53 or P53 or PALB2 or RAD51* or R51H3 or BROVCA* or TRAD or BARD1 or MLH1 or MSH2 or MSH6 or PMS2).tw,kf.
32	("breast cancer gene 1" or "breast cancer gene 2").tw,kf.
33	Rad51 protein/
34	ATM protein/
35	((Ataxia telangiectasia adj1 mutated adj1 (protein* or kinase*)) or ATM or AT1 or ATA or ATC or ATD or ATDC or ATE or TEL1 or TELO1).tw,kf.
36	checkpoint kinase 2/
37	((((checkpoint or check point or serine threonine) adj2 (protein* or kinase*)) or CHEK2 or CDS1 or CHK2 or HuCds1 or LFS2 or PP1425 or RAD53 or hCds1 or hchk2).tw,kf.
38	small cell carcinoma/
39	genetics/
40	38 and 39
41	(small cell adj2 (cancer* or carcinoma*) adj2 gene*).tw,kf.
42	(SMARCA4 or BRG1 or CSS4 or SNF2 or SWI2 or MRD16 or RTPS2 or BAF190 or SNF2L4 or SNF2LB or hSNF2b or BAF190A or SNF2-beta).tw,kf.
43	androblastoma/ or Sertoli cell tumor/ or Leydig cell tumor/
44	((((Sertoli or leydig) adj3 (tumo?* or adenoma* or cancer* or carcinoma* or neoplas* or metasta*)) or arrhenoblastoma* or andr?oblastoma* or SLCT or gynandroblastoma*).tw,kf.
45	(DICER?? or DCR1 or GLOW or MNG1 or aviD or HERNA or RMSE2 or K12H4?8-LIKE).tw,kf.
46	epithelial cell adhesion molecule/
47	Epithelial cell adhesion molecule*.tw,kf.
48	(EPCAM* or EP CAM or ESA or KSA or M4S1 or MK-1 or DIAR5 or EGP??? or Ly74 or gp40 or CD326 or GA733?? or GA 733 or KS1?4 or MIC18 or TROP1 or BerEp4 or HNPCC8 or LYNCH8 or MOC-31 or Ber-Ep4 or TACSTD1).tw,kf.
49	or/8-37,40-48
50	7 and 49
51	(CANRISK or (cancer risk adj1 (tool or model*))).ti,ab,kf.
52	multifactorial inheritance/
53	((multifactor* or polygenic or polygene* or multigenic or oligogenic) adj2 (inherit* or trait* or character* or disease*).ti,ab,kf.
54	((complex or heterogene*) adj2 (inherit* or trait*).ti,ab,kf.
55	((polygenic or polygenetic or genome-wide) adj2 (score or risk or index or indices or study or studies)).ti,ab,kf.
56	genetic epigenesis/
57	(epigene* adj2 (process* or change* or modif* or program* or misprogram*).ti,ab,kf.
58	age/ or groups by age/ or lifestyle/ or body height/

#	Searches
59	((age? or birth cohort* or lifestyle or life style or "way* adj1 life" or height or stature) adj2 (cancer* or neoplas* or carcino* or malignan* or tumo?r* or adenocarcinoma* or sarcoma* or angiosarcoma* or lymphoma* or leiomyosarcoma* or metasta* or risk*)).ti,ab,kf.
60	((lifetime or life time or personal*) adj1 risk).ti,ab.
61	((personal* or lifestyle or life style) adj2 (information or survey* or question*)).ti,ab,kf.
62	body mass/ or body size/ or body weight/ or body composition/ or body weight gain/ or obesity/
63	((((body adj2 (mass or weight or size or fat or fatness or composition)) or BMI or quetelet index or skin fold* or skinfold* or (weight adj2 (manag* or gain* or increas* or excess or chang*)) or (fat adj3 (percent* or distribution))) adj2 (cancer* or neoplas* or carcino* or malignan* or tumo?r* or adenocarcinoma* or sarcoma* or angiosarcoma* or lymphoma* or leiomyosarcoma* or metasta* or risk*)).ti,ab,kf.
64	drinking behavior/ or smoking/ or "tobacco use"/
65	((((alcohol* adj2 (drink* or imbib* or intake or consumption or consum* or binge or abus* or frequenc* or behavio?r* or use* or using or problem*)) or smoking or smoke* or tobacco* or nicotin* or cigar* or cigs or ecig* or e-cig or e-voke* or vape* or vaping) adj2 (cancer* or neoplas* or carcino* or malignan* or tumo?r* or adenocarcinoma* or sarcoma* or angiosarcoma* or lymphoma* or leiomyosarcoma* or metasta* or risk*)).ti,ab,kf.
66	parity/ or reproductive history/ or puberty/ or menarche/ or menopause/
67	((parity or nullipar* or primipar* or primip or multipar* or para or offspring or menarche or menstrua* or menses or menorrhoea or pubert* or menopaus* or perimenopaus* or peri menopaus* or postmenopaus* or post menopaus* or POF or ((reproductive or birth* or pregnanc*) adj2 (histor* or factor*)) adj2 (cancer* or neoplas* or carcino* or malignan* or tumo?r* or adenocarcinoma* or sarcoma* or angiosarcoma* or lymphoma* or leiomyosarcoma* or metasta* or risk*)).ti,ab,kf.
68	hormone substitution/ or estrogen/ or estradiol/ or contraceptive agent/ or oral contraceptive agent/ or hormonal contraception/ or ovulation inhibition/
69	((((hormon* adj3 (therap* or substitut* or replacement or exogenous)) or ((oestrogen* or estrogen* or oestradiol or estradiol or estrone or oestrone or progest* or medroxyprogest*) adj3 (therap* or substitut* or replacement or exogenous))) adj2 (cancer* or neoplas* or carcino* or malignan* or tumo?r* or adenocarcinoma* or sarcoma* or angiosarcoma* or lymphoma* or leiomyosarcoma* or metasta* or risk*)).ti,ab,kf.
70	(HRT or HT or MHT).ti,ab,kf.
71	((((oral or hormon*) adj3 contracept*) or (ovulat* adj2 (inhibit* or suppress* or block*))) adj2 (cancer* or neoplas* or carcino* or malignan* or tumo?r* or adenocarcinoma* or sarcoma* or angiosarcoma* or lymphoma* or leiomyosarcoma* or metasta* or risk*)).ti,ab,kf.
72	birth control pill*.ti,ab,kf.
73	endometriosis/ or adenomyosis/
74	((endometriosis or endometrioma* or adenomyosis or adenomyoma* or adenometritis or adenomyositis or adenomyometritis) adj2 (cancer* or neoplas* or carcino* or malignan* or tumo?r* or adenocarcinoma* or sarcoma* or angiosarcoma* or lymphoma* or leiomyosarcoma* or metasta* or risk*)).ti,ab,kf.
75	exp population group/ or demography/ or migration/
76	((ethnic* or nation* or race or racial or minority or minorities or indigenous or demograph* or population or ((count* or place) adj3 (birth or born or origin*))) adj4 (cancer* or neoplas* or carcino* or malignan* or tumo?r* or adenocarcinoma* or sarcoma* or angiosarcoma* or lymphoma* or leiomyosarcoma* or metasta* or risk*)).ti,ab,kf.
77	((family or personal) adj2 history).ti,ab,kf.
78	((genetic or environment* or epidemiolog* or hormonal) adj2 risk*).ti,ab,kf.
79	or/51-78
80	mass screening/
81	((screen* or detect* or test* or diagnos*) adj2 (cancer* or neoplas* or carcino* or malignan* or tumo?r* or adenocarcinoma* or sarcoma* or angiosarcoma* or lymphoma* or leiomyosarcoma* or metasta* or risk*)).ti,ab,kf.
82	exp Early Diagnosis/
83	(early adj2 (diagnos? or detect* or identif*) adj3 (cancer* or neoplas* or carcino* or malignan* or tumo?r* or adenocarcinoma* or sarcoma* or angiosarcoma* or lymphoma* or leiomyosarcoma* or metasta* or risk*)).ti,ab,kf.
84	((assess* or probability or predict* or scor*) adj3 (tool* or model* or system* or test* or threshold*)).ti,ab,kf.
85	risk/ or epidemiology/
86	(risk adj3 (tool* or assess* or interval* or analys? or estimat* or predict* or factor* or model* or scor* or stratif* or test* or evaluat* or accuracy or accurate or epidemiolog*)).ti,ab,kf.
87	or/80-86
88	79 and 87
89	50 and 88
90	letter.pt. or letter/
91	note.pt.
92	editorial.pt.

#	Searches
93	case report/ or case study/
94	(letter or comment*).ti.
95	animal/ not human/
96	nonhuman/
97	exp Animal Experiment/
98	exp Experimental Animal/
99	animal model/
100	exp Rodent/
101	(rat or rats or mouse or mice or rodent*).ti.
102	or/90-101
103	89 not 102
104	(conference abstract* or conference review or conference paper or conference proceeding).db,pt,su.
105	103 not 104
106	limit 105 to English language
107	health economics/
108	exp economic evaluation/
109	exp health care cost/
110	exp fee/
111	budget/
112	funding/
113	resource allocation/
114	budget*.ti,ab.
115	cost*.ti,ab.
116	(economic* or pharmaco?economic*).ti,ab.
117	(price* or pricing*).ti,ab.
118	(financ* or fee or fees or expenditure* or saving*).ti,ab.
119	(value adj2 (money or monetary)).ti,ab.
120	resourc* allocat*.ti,ab.
121	(fund or funds or funding* or funded).ti,ab.
122	(ration or rations or rationing* or rationed).ti,ab.
123	or/107-122
124	106 and 123

Database: INAHTA International HTA Database

Date of last search: 27/03/2023

#	Searches
19	LIMIT #18 TO 2022-2023
18	#17 AND #8
17	#16 OR #15 OR #14 OR #13 OR #12 OR #11 OR #10 OR #9
16	((BRCA* or IRIS or PSCP or BRCC1 or BRIP1 or BACH1 or FANC* or PNCA* or RNF53 or PPP1R53 or FAD* or FACD or GLM3 or BRCC2 or XRCC11 or TP53 or P53 or PALB2 or RAD51* or R51H3 or BROVCA* or TRAD or BARD1 or MLH1 or MSH2 or MSH6 or PMS2 or DICER1 or SMARCA4 or STK11 or LKB1 or PJS or hLKB1 or ATM or AT1 or ATA or ATC or ATD or ATDC or ATE or TEL1 or TELO1 or CHEK2 or CDS1 or CHK2 or HuCds1 or LFS2 or PP1425 or RAD53 or hCds1 or hchk2 or MUTYH or MYH or FAP or AFAP or APC))[Title] OR ((BRCA* or IRIS or PSCP or BRCC1 or BRIP1 or BACH1 or FANC* or PNCA* or RNF53 or PPP1R53 or FAD* or FACD or GLM3 or BRCC2 or XRCC11 or TP53 or P53 or PALB2 or RAD51* or R51H3 or BROVCA* or TRAD or BARD1 or MLH1 or MSH2 or MSH6 or PMS2 or DICER1 or SMARCA4 or STK11 or LKB1 or PJS or hLKB1 or ATM or AT1 or ATA or ATC or ATD or ATDC or ATE or TEL1 or TELO1 or CHEK2 or CDS1 or CHK2 or HuCds1 or LFS2 or PP1425 or RAD53 or hCds1 or hchk2 or MUTYH or MYH or FAP or AFAP or APC))[Title] OR ((BRCA* or IRIS or PSCP or BRCC1 or BRIP1 or BACH1 or FANC* or PNCA* or RNF53 or PPP1R53 or FAD* or FACD or GLM3 or BRCC2 or XRCC11 or TP53 or P53 or PALB2 or RAD51* or R51H3 or BROVCA* or TRAD or BARD1 or MLH1 or MSH2 or MSH6 or PMS2 or DICER1 or SMARCA4 or STK11 or LKB1 or PJS or hLKB1 or ATM or AT1 or ATA or ATC or ATD or ATDC or ATE or TEL1 or TELO1 or CHEK2 or CDS1 or CHK2 or HuCds1 or LFS2 or PP1425 or RAD53 or hCds1 or hchk2 or MUTYH or MYH or FAP or AFAP or APC))[Title] OR ((BRCA* or IRIS or PSCP or BRCC1 or BRIP1 or BACH1 or FANC* or PNCA* or RNF53 or

#	Searches
	PPP1R53 or FAD* or FACD or GLM3 or BRCC2 or XRCC11 or TP53 or P53 or PALB2 or RAD51* or R51H3 or BROVCA* or TRAD or BARD1 or MLH1 or MSH2 or MSH6 or PMS2 or DICER1 or SMARCA4 or STK11 or LKB1 or PJS or hLKB1 or ATM or AT1 or ATA or ATC or ATD or ATDC or ATE or TEL1 or TELO1 or CHEK2 or CDS1 or CHK2 or HuCds1 or LFS2 or PP1425 or RAD53 or hCds1 or hchk2 or MUTYH or MYH or FAP or AFAP or APC)[abs]
15	((carrier* or gene*) AND mutat*)[Title] OR ((carrier* or gene*) AND mutat*)[abs]
14	("hereditary breast and ovarian cancer" or HBOC or "Li Fraumeni syndrome" or SBLA or LFS)[Title] OR ("hereditary breast and ovarian cancer" or HBOC or "Li Fraumeni syndrome" or SBLA or LFS)[abs]
13	((familial or inherit* or heredit* or predispos* or pre dispos* or susceptib*) AND (cancer* or neoplas* or carcino* or malignan* or tumo?r* or adenocarcinoma* or sarcoma* or angiosarcoma* or lymphoma* or leiomyosarcoma* or metasta*)) [Title] OR ((familial or inherit* or heredit* or predispos* or pre dispos* or susceptib*) AND (cancer* or neoplas* or carcino* or malignan* or tumo?r* or adenocarcinoma* or sarcoma* or angiosarcoma* or lymphoma* or leiomyosarcoma* or metasta*)) [abs]
12	((MUTYH or MYH or FAP or AFAP or APC)[Title] OR ((MUTYH or MYH or FAP or AFAP or APC)[abs]
11	((hereditary or inherit* or familial or adenomato* or attenuated) AND polyp* AND (coli or colon or colorectal or bowel or rectum or intestin* or gastrointestin* or syndrome* or multiple)) [Title] OR ((hereditary or inherit* or familial or adenomato* or attenuated) AND polyp* AND (coli or colon or colorectal or bowel or rectum or intestin* or gastrointestin* or syndrome* or multiple)) [abs]
10	((peutz* or intestin* polyposis or STK11 or LKB1 or PJS or hLKB1)[Title] OR ((peutz* or intestin* polyposis or STK11 or LKB1 or PJS or hLKB1)[abs]
9	((hereditary or inherit* or familial) AND (nonpolyposis or non polyposis) AND (colon or colorectal or bowel) AND cancer*) [Title] OR ((hereditary or inherit* or familial) AND (nonpolyposis or non polyposis) AND (colon or colorectal or bowel) AND cancer*) [abs]
8	#7 OR #3
7	#6 OR #5 OR #4
6	((breast* or mammary) AND (cancer* or neoplas* or carcino* or malignan* or tumo?r* or adenocarcinoma* or sarcoma* or angiosarcoma* or lymphoma* or leiomyosarcoma* or dcis or ductal or infiltrat* or intraductal* or lobular or medullary or metasta*)) [Title] OR ((breast* or mammary) AND (cancer* or neoplas* or carcino* or malignan* or tumo?r* or adenocarcinoma* or sarcoma* or angiosarcoma* or lymphoma* or leiomyosarcoma* or dcis or ductal or infiltrat* or intraductal* or lobular or medullary or metasta*)) [abs]
5	"Neoplasms, Ductal, Lobular, and Medullary"[mh]
4	"Breast Neoplasms"[mhe]
3	#2 OR #1
2	((ovar* AND (cancer* or neoplas* or carcino* or malignan* or tumo?r* or adenocarcinoma* or sarcoma* or angiosarcoma* or lymphoma* or leiomyosarcoma* or metasta*)) [Title] OR ((ovar* AND (cancer* or neoplas* or carcino* or malignan* or tumo?r* or adenocarcinoma* or sarcoma* or angiosarcoma* or lymphoma* or leiomyosarcoma* or metasta*)) [abs]
1	"Ovarian Neoplasms"[mhe]

A combined update search was run for the following two questions:

- [K] What are the benefits and risks of surveillance for women at increased risk of familial ovarian cancer?
- [L] How effective are different methods of surveillance for women at increased risk of familial ovarian cancer?

Database: Ovid MEDLINE(R) ALL

Date of last search: 27/03/2023

#	Searches
1	exp Ovarian Neoplasms/
2	(ovar* adj5 (cancer* or neoplas* or carcino* or malignan* or tumo?r* or adenocarcinoma* or sarcoma* or angiosarcoma* or lymphoma* or leiomyosarcoma* or metasta*).tw,kf.
3	or/1-2
4	exp Breast Neoplasms/
5	exp "Neoplasms, Ductal, Lobular, and Medullary"/

#	Searches
6	((breast* or mammary) adj5 (cancer* or neoplas* or carcino* or malignan* or tumo?*r* or adenocarcinoma* or sarcoma* or angiosarcoma* or lymphoma* or leiomyosarcoma* or dcis or ductal or infiltrat* or intraductal* or lobular or medullary or metasta*)).tw,kf.
7	or/4-6
8	3 or 7
9	exp Genetic Predisposition to Disease/
10	Pedigree/
11	exp Neoplastic Syndromes, Hereditary/
12	((hereditary or inherit* or familial) adj3 (nonpolyposis or non polyposis) adj3 (colon or colorectal or bowel) adj3 (cancer* or neoplas* or carcino* or malignan* or tumo?*r* or adenocarcinoma* or sarcoma* or angiosarcoma* or lymphoma* or leiomyosarcoma* or metasta*)).tw,kf.
13	((Lynch or Muir Torre) adj2 (syndrome* or cancer*)).tw,kf.
14	HNPCC.tw,kf.
15	(peutz* or intestin* polyposis or STK11 or LKB1 or PJS or hLKB1 or (perior* adj1 lentigino*)).tw,kf.
16	((hamartoma* or "polyps and spots" or cowden*) adj2 (syndrome* or polyp*)).tw,kf.
17	((hereditary or inherit* or familial or adenomato* or attenuated) adj3 polyp* adj3 (coli or colon or colorectal or bowel or rectum or intestin* or gastrointestinal* or syndrome* or multiple)).tw,kf.
18	gardner* syndrome*.tw,kf.
19	(MUTYH or MYH or FAP or AFAP or APC).tw,kf.
20	((familial or inherit* or heredit* or predispos* or pre dispos* or susceptib* or ancestr* or genealog* or descent) adj2 (cancer* or neoplas* or carcino* or malignan* or tumo?*r* or adenocarcinoma* or sarcoma* or angiosarcoma* or lymphoma* or leiomyosarcoma* or metasta*)).tw,kf.
21	("hereditary breast and ovarian cancer" or HBOC or Li Fraumeni syndrome or SBLA or LFS).tw,kf.
22	(famil* adj2 histor* adj2 (cancer* or neoplas* or carcino* or malignan* or tumo?*r* or adenocarcinoma* or sarcoma* or angiosarcoma* or lymphoma* or leiomyosarcoma* or metasta*)).tw,kf.
23	risk factors/
24	((risk* or probabil*) adj3 (high* or increas* or factor* or rais*) adj3 (mutat* or malignan* or gene* or variant*)).tw,kf.
25	((carrier* or gene*) adj3 mutat*).tw,kf.
26	exp Genes, Tumor Suppressor/
27	exp Tumor Suppressor Proteins/
28	((tumo?*r* or cancer* or metastas?s or growth*) adj2 (suppress* adj1 (gene* or protein*))).tw,kf.
29	(anti oncogene* or antioncogene* or onco suppressor* or oncosuppressor*).tw,kf.
30	exp Fanconi Anemia Complementation Group Proteins/
31	(Fanconi An?emia adj3 protein*).tw,kf.
32	(BRCA* or IRIS or PSCP or BRCC1 or BRIP1 or BACH1 or FANC* or PNCA* or RNF53 or PPP1R53 or FAD* or FACD or GLM3 or BRCC2 or XRCC11 or TP53 or P53 or PALB2 or RAD51* or R51H3 or BROVCA* or TRAD or BARD1 or MLH1 or MSH2 or MSH6 or PMS2).tw,kf.
33	("breast cancer gene 1" or "breast cancer gene 2").tw,kf.
34	Rad51 Recombinase/
35	Ataxia Telangiectasia Mutated Proteins/
36	((Ataxia telangiectasia adj1 mutated adj1 (protein* or kinase*)) or ATM or AT1 or ATA or ATC or ATD or ATDC or ATE or TEL1 or TELO1).tw,kf.
37	Checkpoint Kinase 2/
38	((((checkpoint or check point or serine threonine) adj2 (protein* or kinase*)) or CHEK2 or CDS1 or CHK2 or HuCds1 or LFS2 or PP1425 or RAD53 or hCds1 or hchk2).tw,kf.
39	Carcinoma, Small Cell/ge [Genetics]
40	(small cell adj2 (cancer* or carcinoma*) adj2 gene*).tw,kf.
41	(SMARCA4 or BRG1 or CSS4 or SNF2 or SWI2 or MRD16 or RTPS2 or BAF190 or SNF2L4 or SNF2LB or hSNF2b or BAF190A or SNF2-beta).tw,kf.
42	exp Sertoli-Leydig Cell Tumor/
43	((Sertoli or leydig) adj3 (tumo?*r* or adenoma* or cancer* or carcinoma* or neoplas* or metasta*)) or arrhenoblastoma* or andr?oblastoma* or SLCT or gynandroblastoma*).tw,kf.
44	(DICER?? or DCR1 or GLOW or MNG1 or aviD or HERNA or RMSE2 or K12H4?8-LIKE).tw,kf.
45	Epithelial Cell Adhesion Molecule/
46	Epithelial cell adhesion molecule*.tw,kf.

#	Searches
47	(EPCAM* or EP CAM or ESA or KSA or M4S1 or MK-1 or DIAR5 or EGP??? or Ly74 or gp40 or CD326 or GA733?? or GA 733 or KS1?4 or MIC18 or TROP1 or BerEp4 or HNPCC8 or LYNCH8 or MOC-31 or Ber-Ep4 or TACSTD1).tw,kf.
48	or/9-47
49	8 and 48
50	CA-125 Antigen/
51	(CA 125 or CA125).ti,ab,kf.
52	Ultrasonography/
53	(ultrasound* or ultrason* or ultra sound* or sonograph* or ultrasonograph* or echograph* or echotomograph*).ti,ab,kf.
54	(transvaginal or trans vaginal or endovaginal or endo vaginal or pelvic or cervi*).ti,ab,kf.
55	(TVUS or TVS).ti,ab.
56	Tomography, X-Ray Computed/
57	((CAT or CT or comput* or electron beam or positron emission or PET) adj2 (scan* or x ray* or xray* or tomograph*or screen*).ti,ab,kf.
58	exp Magnetic Resonance Imaging/
59	((magnetic resonance adj2 (imag* or scan* or screen*)) or MRI).ti,ab,kf.
60	("Risk of ovarian cancer algorithm" or ROCA).ti,ab,kf.
61	algorithms/
62	algorithm*.ti,ab,kf.
63	"predictive value of tests"/ or clinical decision rules/
64	((predict* or clinical* or decision) adj2 (value* or test* or rule* or support)).ti,ab,kf.
65	exp models, statistical/
66	((math* or statistic*) adj2 (model* or evaluat* or technique* or assess* or formula* or analys?s or calculat*).ti,ab,kf.
67	Mass Screening/ or Watchful Waiting/
68	(surveillance or watchful wait* or screen*).ti,ab,kf.
69	or/50-68
70	49 and 69
71	letter/
72	editorial/
73	news/
74	exp historical article/
75	Anecdotes as Topic/
76	comment/
77	case reports/
78	(letter or comment*).ti.
79	or/71-78
80	randomized controlled trial/ or random*.ti,ab.
81	79 not 80
82	animals/ not humans/
83	exp Animals, Laboratory/
84	exp Animal Experimentation/
85	exp Models, Animal/
86	exp Rodentia/
87	(rat or rats or mouse or mice or rodent*).ti.
88	or/81-87
89	70 not 88
90	limit 89 to English language
91	Economics/
92	Value of life/
93	exp "Costs and Cost Analysis"/
94	exp Economics, Hospital/

#	Searches
95	exp Economics, Medical/
96	exp Resource Allocation/
97	Economics, Nursing/
98	Economics, Pharmaceutical/
99	exp "Fees and Charges"/
100	exp Budgets/
101	budget*.ti,ab.
102	cost*.ti,ab.
103	(economic* or pharmaco?economic*).ti,ab.
104	(price* or pricing*).ti,ab.
105	(financ* or fee or fees or expenditure* or saving*).ti,ab.
106	(value adj2 (money or monetary)).ti,ab.
107	resourc* allocat*.ti,ab.
108	(fund or funds or funding* or funded).ti,ab.
109	(ration or rations or rationing* or rationed).ti,ab.
110	ec.fs.
111	or/91-110
112	90 and 111

Database: Embase

Date of last search: 27/03/2023

#	Searches
1	exp ovary tumor/
2	(ova* adj5 (cancer* or neoplas* or carcino* or malignan* or tumo?*r* or adenocarcinoma* or sarcoma* or angiosarcoma* or lymphoma* or leiomyosarcoma* or metasta*).tw,kf.
3	or/1-2
4	exp breast tumor/
5	((breast* or mammary) adj5 (cancer* or neoplas* or carcino* or malignan* or tumo?*r* or adenocarcinoma* or sarcoma* or angiosarcoma* or lymphoma* or leiomyosarcoma* or dcis or ductal or infiltrat* or intraductal* or lobular or medullary or metasta*).tw,kf.
6	or/4-5
7	3 or 6
8	exp genetic predisposition/
9	pedigree/
10	exp hereditary tumor syndrome/
11	((hereditary or inherit* or familial) adj3 (nonpolyposis or non polyposis) adj3 (colon or colorectal or bowel) adj3 (cancer* or neoplas* or carcino* or malignan* or tumo?*r* or adenocarcinoma* or sarcoma* or angiosarcoma* or lymphoma* or leiomyosarcoma* or metasta*).tw,kf.
12	((Lynch or Muir Torre) adj2 (syndrome* or cancer*).tw,kf.
13	HNPCC.tw,kf.
14	(peutz* or intestin* polyposis or STK11 or LKB1 or PJS or hLKB1 or (perior* adj1 lentigino*).tw,kf.
15	((hamartoma* or "polyps and spots" or cowden*) adj2 (syndrome* or polyp*).tw,kf.
16	((hereditary or inherit* or familial or adenomato* or attenuated) adj3 polyp* adj3 (coli or colon or colorectal or bowel or rectum or intestin* or gastrointestin* or syndrome* or multiple)).tw,kf.
17	gardner* syndrome*.tw,kf.
18	(MUTYH or MYH or FAP or AFAP or APC).tw,kf.
19	((familial or inherit* or heredit* or predispos* or pre dispos* or susceptib* or ancestr* or genealog* or descent) adj2 (cancer* or neoplas* or carcino* or malignan* or tumo?*r* or adenocarcinoma* or sarcoma* or angiosarcoma* or lymphoma* or leiomyosarcoma* or metasta*).tw,kf.
20	("hereditary breast and ovarian cancer" or HBOC or Li Fraumeni syndrome or SBLA or LFS).tw,kf.
21	(famil* adj2 histor* adj2 (cancer* or neoplas* or carcino* or malignan* or tumo?*r* or adenocarcinoma* or sarcoma* or angiosarcoma* or lymphoma* or leiomyosarcoma* or metasta*).tw,kf.
22	risk factor/

Ovarian cancer: identifying and managing familial and genetic risk, Supplement 2 – Economic literature DRAFT for Consultation (September 2023)

#	Searches
23	((risk* or probabil*) adj3 (high* or increas* or factor* or rais*) adj3 (mutat* or malignan* or gene* or variant*)).tw,kf.
24	((carrier* or gene*) adj3 mutat*).tw,kf.
25	tumor suppressor gene/
26	exp tumor suppressor protein/
27	((tumo?* or cancer* or metastas?s or growth*) adj2 (suppress* adj1 (gene* or protein*))).tw,kf.
28	(anti oncogene* or antioncogene* or onco suppressor* or oncosuppressor*).tw,kf.
29	Fanconi anemia protein/
30	(Fanconi An?emia adj3 protein*).tw,kf.
31	(BRCA* or IRIS or PSCP or BRCC1 or BRIP1 or BACH1 or FANC* or PNCA* or RNF53 or PPP1R53 or FAD* or FADC or GLM3 or BRCC2 or XRCC11 or TP53 or P53 or PALB2 or RAD51* or R51H3 or BROVCA* or TRAD or BARD1 or MLH1 or MSH2 or MSH6 or PMS2).tw,kf.
32	("breast cancer gene 1" or "breast cancer gene 2").tw,kf.
33	Rad51 protein/
34	ATM protein/
35	((Ataxia telangiectasia adj1 mutated adj1 (protein* or kinase*)) or ATM or AT1 or ATA or ATC or ATD or ATDC or ATE or TEL1 or Telo1).tw,kf.
36	checkpoint kinase 2/
37	((((checkpoint or check point or serine threonine) adj2 (protein* or kinase*)) or CHEK2 or CDS1 or CHK2 or HuCds1 or LFS2 or PP1425 or RAD53 or hCds1 or hchk2).tw,kf.
38	small cell carcinoma/
39	genetics/
40	38 and 39
41	(small cell adj2 (cancer* or carcinoma*) adj2 gene*).tw,kf.
42	(SMARCA4 or BRG1 or CSS4 or SNF2 or SWI2 or MRD16 or RTPS2 or BAF190 or SNF2L4 or SNF2LB or hSNF2b or BAF190A or SNF2-beta).tw,kf.
43	androblastoma/ or Sertoli cell tumor/ or Leydig cell tumor/
44	((Sertoli or leydig) adj3 (tumo?* or adenoma* or cancer* or carcinoma* or neoplas* or metasta*)) or arrhenoblastoma* or andr?oblastoma* or SLCT or gynandroblastoma*).tw,kf.
45	(DICER?? or DCR1 or GLOW or MNG1 or aviD or HERNA or RMSE2 or K12H4?8-LIKE).tw,kf.
46	epithelial cell adhesion molecule/
47	Epithelial cell adhesion molecule*.tw,kf.
48	(EPCAM* or EP CAM or ESA or KSA or M4S1 or MK-1 or DIAR5 or EGP??? or Ly74 or gp40 or CD326 or GA733?? or GA 733 or KS1?4 or MIC18 or TROP1 or BerEp4 or HNPCC8 or LYNCH8 or MOC-31 or Ber-Ep4 or TACSTD1).tw,kf.
49	or/8-37,40-48
50	7 and 49
51	CA 125 antigen/
52	(CA 125 or CA125).ti,ab,kf.
53	echography/ or transvaginal echography/
54	(ultrasound* or ultrason* or ultra sound* or sonograph* or ultrasonograph* or echograph* or echotomograph*).ti,ab,kf.
55	(transvaginal or trans vaginal or endovaginal or endo vaginal or pelvic or cervi*).ti,ab,kf.
56	(TVUS or TVS).ti,ab.
57	x-ray computed tomography/
58	((CAT or CT or comput* or electron beam or positron emission or PET) adj2 (scan* or x ray* or xray* or tomograph* or screen*)).ti,ab,kf.
59	nuclear magnetic resonance imaging/
60	((magnetic resonance adj2 (imag* or scan* or screen*)) or MRI).ti,ab,kf.
61	("Risk of ovarian cancer algorithm" or ROCA).ti,ab,kf.
62	algorithm/
63	algorithm*.ti,ab,kf.
64	predictive value/
65	clinical decision rule/
66	((predict* or clinical* or decision) adj2 (value* or test* or rule* or support)).ti,ab,kf.

#	Searches
67	statistical model/
68	((math* or statistic*) adj2 (model* or evaluat* or technique* or assess* or formula* or analys?s or calculat*)).ti,ab,kf.
69	screening/ or mass screening/ or watchful waiting/
70	(surveillance or watchful wait* or screen*).ti,ab,kf.
71	or/51-70
72	50 and 71
73	letter.pt. or letter/
74	note.pt.
75	editorial.pt.
76	case report/ or case study/
77	(letter or comment*).ti.
78	or/73-77
79	randomized controlled trial/ or random*.ti,ab.
80	78 not 79
81	animal/ not human/
82	nonhuman/
83	exp Animal Experiment/
84	exp Experimental Animal/
85	animal model/
86	exp Rodent/
87	(rat or rats or mouse or mice or rodent*).ti.
88	or/80-87
89	72 not 88
90	(conference abstract* or conference review or conference paper or conference proceeding).db,pt,su.
91	89 not 90
92	limit 91 to English language
93	health economics/
94	exp economic evaluation/
95	exp health care cost/
96	exp fee/
97	budget/
98	funding/
99	resource allocation/
100	budget*.ti,ab.
101	cost*.ti,ab.
102	(economic* or pharmaco?economic*).ti,ab.
103	(price* or pricing*).ti,ab.
104	(financ* or fee or fees or expenditure* or saving*).ti,ab.
105	(value adj2 (money or monetary)).ti,ab.
106	resourc* allocat*.ti,ab.
107	(fund or funds or funding* or funded).ti,ab.
108	(ration or rations or rationing* or rationed).ti,ab.
109	or/93-108
110	92 and 109

Database: INAHTA International HTA Database

Date of last search: 27/03/2023

#	Searches
18	#17 AND #8
17	#16 OR #15 OR #14 OR #13 OR #12 OR #11 OR #10 OR #9


Ovarian cancer: identifying and managing familial and genetic risk, Supplement 2 – Economic literature DRAFT for Consultation (September 2023)

#	Searches
16	((BRCA* or IRIS or PSCP or BRCC1 or BRIP1 or BACH1 or FANC* or PNCA* or RNF53 or PPP1R53 or FAD* or FACD or GLM3 or BRCC2 or XRCC11 or TP53 or P53 or PALB2 or RAD51* or R51H3 or BROVCA* or TRAD or BARD1 or MLH1 or MSH2 or MSH6 or PMS2 or DICER1 or SMARCA4 or STK11 or LKB1 or PJS or hLKB1 or ATM or AT1 or ATA or ATC or ATD or ATDC or ATE or TEL1 or TELO1 or CHEK2 or CDS1 or CHK2 or HuCds1 or LFS2 or PP1425 or RAD53 or hCds1 or hchk2 or MUTYH or MYH or FAP or AFAP or APC))[Title] OR ((BRCA* or IRIS or PSCP or BRCC1 or BRIP1 or BACH1 or FANC* or PNCA* or RNF53 or PPP1R53 or FAD* or FACD or GLM3 or BRCC2 or XRCC11 or TP53 or P53 or PALB2 or RAD51* or R51H3 or BROVCA* or TRAD or BARD1 or MLH1 or MSH2 or MSH6 or PMS2 or DICER1 or SMARCA4 or STK11 or LKB1 or PJS or hLKB1 or ATM or AT1 or ATA or ATC or ATD or ATDC or ATE or TEL1 or TELO1 or CHEK2 or CDS1 or CHK2 or HuCds1 or LFS2 or PP1425 or RAD53 or hCds1 or hchk2 or MUTYH or MYH or FAP or AFAP or APC))[Title] OR ((BRCA* or IRIS or PSCP or BRCC1 or BRIP1 or BACH1 or FANC* or PNCA* or RNF53 or PPP1R53 or FAD* or FACD or GLM3 or BRCC2 or XRCC11 or TP53 or P53 or PALB2 or RAD51* or R51H3 or BROVCA* or TRAD or BARD1 or MLH1 or MSH2 or MSH6 or PMS2 or DICER1 or SMARCA4 or STK11 or LKB1 or PJS or hLKB1 or ATM or AT1 or ATA or ATC or ATD or ATDC or ATE or TEL1 or TELO1 or CHEK2 or CDS1 or CHK2 or HuCds1 or LFS2 or PP1425 or RAD53 or hCds1 or hchk2 or MUTYH or MYH or FAP or AFAP or APC))[Title] OR ((BRCA* or IRIS or PSCP or BRCC1 or BRIP1 or BACH1 or FANC* or PNCA* or RNF53 or PPP1R53 or FAD* or FACD or GLM3 or BRCC2 or XRCC11 or TP53 or P53 or PALB2 or RAD51* or R51H3 or BROVCA* or TRAD or BARD1 or MLH1 or MSH2 or MSH6 or PMS2 or DICER1 or SMARCA4 or STK11 or LKB1 or PJS or hLKB1 or ATM or AT1 or ATA or ATC or ATD or ATDC or ATE or TEL1 or TELO1 or CHEK2 or CDS1 or CHK2 or HuCds1 or LFS2 or PP1425 or RAD53 or hCds1 or hchk2 or MUTYH or MYH or FAP or AFAP or APC))[abs]
15	(((carrier* or gene*) AND mutat*)) [Title] OR (((carrier* or gene*) AND mutat*)) [abs]
14	((("hereditary breast and ovarian cancer" or HBOC or "Li Fraumeni syndrome" or SBLA or LFS)) [Title] OR ((("hereditary breast and ovarian cancer" or HBOC or "Li Fraumeni syndrome" or SBLA or LFS)) [abs]
13	(((familial or inherit* or heredit* or predispos* or pre dispos* or susceptib*) AND (cancer* or neoplas* or carcino* or malignan* or tumo?r* or adenocarcinoma* or sarcoma* or angiosarcoma* or lymphoma* or leiomyosarcoma* or metasta*)) [Title] OR (((familial or inherit* or heredit* or predispos* or pre dispos* or susceptib*) AND (cancer* or neoplas* or carcino* or malignan* or tumo?r* or adenocarcinoma* or sarcoma* or angiosarcoma* or lymphoma* or leiomyosarcoma* or metasta*)) [abs]
12	((MUTYH or MYH or FAP or AFAP or APC) [Title] OR ((MUTYH or MYH or FAP or AFAP or APC) [abs]
11	(((hereditary or inherit* or familial or adenomato* or attenuated) AND polyp* AND (coli or colon or colorectal or bowel or rectum or intestin* or gastrointestin* or syndrome* or multiple)) [Title] OR (((hereditary or inherit* or familial or adenomato* or attenuated) AND polyp* AND (coli or colon or colorectal or bowel or rectum or intestin* or gastrointestin* or syndrome* or multiple)) [abs]
10	((peutz* or intestin* polyposis or STK11 or LKB1 or PJS or hLKB1) [Title] OR ((peutz* or intestin* polyposis or STK11 or LKB1 or PJS or hLKB1) [abs]
9	(((hereditary or inherit* or familial) AND (nonpolyposis or non polyposis) AND (colon or colorectal or bowel) AND cancer*)) [Title] OR (((hereditary or inherit* or familial) AND (nonpolyposis or non polyposis) AND (colon or colorectal or bowel) AND cancer*)) [abs]
8	#7 OR #3
7	#6 OR #5 OR #4
6	(((breast* or mammary) AND (cancer* or neoplas* or carcino* or malignan* or tumo?r* or adenocarcinoma* or sarcoma* or angiosarcoma* or lymphoma* or leiomyosarcoma* or dcis or ductal or infiltrat* or intraductal* or lobular or medullary or metasta*)) [Title] OR (((breast* or mammary) AND (cancer* or neoplas* or carcino* or malignan* or tumo?r* or adenocarcinoma* or sarcoma* or angiosarcoma* or lymphoma* or leiomyosarcoma* or dcis or ductal or infiltrat* or intraductal* or lobular or medullary or metasta*)) [abs]
5	"Neoplasms, Ductal, Lobular, and Medullary" [mh]
4	"Breast Neoplasms" [mhe]
3	#2 OR #1
2	((ovar* AND (cancer* or neoplas* or carcino* or malignan* or tumo?r* or adenocarcinoma* or sarcoma* or angiosarcoma* or lymphoma* or leiomyosarcoma* or metasta*)) [Title] OR ((ovar* AND (cancer* or neoplas* or carcino* or malignan* or tumo?r* or adenocarcinoma* or sarcoma* or angiosarcoma* or lymphoma* or leiomyosarcoma* or metasta*)) [abs]
1	"Ovarian Neoplasms" [mhe]

1 Economic study selection

2 Economic evidence study selection is shown in Figure 1. The number of included
3 studies for each review question is detailed in Table 1. The list of excluded studies
4 across all reviews with reasons for their exclusion are detailed in Table 2.

5 **Figure 1: Economic study selection**



6
7 [1] This includes 20 studies identified through economic literature searches, as well as 1 study in
8 publication (Sun 2023) and economic modelling conducted for the NICE Familial Breast Cancer
9 Guideline CG164 (published in 2013, last updated in 2019).

10 **Table 1: Included economic studies**

Evidence review	Review question	Number of included studies
[A] information and support	What information and support is needed by women with familial ovarian cancer or who are at increased risk of ovarian cancer (with or without breast cancer), and their families and carers?	NA – Qualitative review
[B] support interventions	Which interventions are effective for supporting women at increased risk of ovarian cancer to make decisions about management options related to this?	2 Manchanda 2016, Tutty 2019
[C] configuration of services	What is the most effective configuration of services for referral, risk assessment and risk management for women at increased risk of ovarian cancer (including fertility, menopause and psychological support services)?	0
[D] optimal methods of assessing the probability	What are the optimal methods of assessing the probability of having a pathogenic variant associated with familial ovarian cancer?	0

Evidence review	Review question	Number of included studies
[E] optimal methods of assessing the absolute risk	What are the optimal methods of assessing the absolute risk of ovarian cancer in women with (or at an increased risk of) a pathogenic variant associated with familial ovarian cancer?	0
[F] carrier probability - any person	At what carrier probability should women people with a family history of cancer suggestive of pathogenic variants in ovarian cancer predisposition genes be offered genetic testing?	4 Hoskins 2019, Kwon 2019, Muller 2019, NICE CG164 2013
[G] carrier probability - family history of syndrome	On the basis of what carrier probability or criteria should a person with a personal or family history suggestive of a clinically defined syndrome associated with an increased risk of ovarian cancer (for example Peutz-Jeghers syndrome) be offered genetic testing?	0
[H] populations with high prevalence	Which populations with a high prevalence of pathogenic variants for familial ovarian cancer would meet the risk threshold for genetic testing?	4 Manchanda 2015, Manchanda 2017, Michaelson-Cohen 2022, Patel 2018
[I] carrier probability - women with ovarian cancer	At what carrier probability should women with ovarian cancer (with or without breast cancer) be offered genetic testing?	5 Eccleston 2017, Hurry 2020, NICE CG164 2013, Moya-Alarcon 2019, Sun 2023 in publication
[J] which genes to included	Which genes should be included in a gene panel when testing for pathogenic variants that increase the risk of familial ovarian cancer?	0
[K] benefits and risks of surveillance	What are the benefits and risks of surveillance for women at increased risk of familial ovarian cancer?	4 Bommer 2022, Muller 2018, Philpott 2022, Yamauchi 2018 ¹
[L] effectiveness of surveillance	How effective are different methods of surveillance for women at increased risk of familial ovarian cancer?	0
[M] preventive medicines	How effective are preventive medicines for reducing the incidence of ovarian cancer for women at increased risk of familial ovarian cancer?	0
[N] risk-reducing surgery	How effective is risk-reducing surgery for women at increased risk of familial ovarian cancer (also considering risk threshold, age and extent and types of surgery)?	5 Bommer 2022, Manchanda 2015, Manchanda 2016, Muller 2018, Yamauchi 2018

Evidence review	Review question	Number of included studies
[O] pathological protocol	What pathological protocol for handling specimens from risk reducing surgery should be followed for risk-reducing surgery for women at increased risk of familial ovarian cancer?	0
[P] hormone replacement therapy after risk-reducing surgery	What are the benefits and risks of hormone replacement therapy after risk-reducing surgery for women at increased risk of familial ovarian cancer?	0

1 [1] Bommer 2022, Müller 2018 and Yamauchi 2018 primarily focused on risk reducing surgery.
 2 However, these studies also incorporated surveillance strategies as comparators and relevant
 3 findings were included in both risk reducing surgery and surveillance reviews.

4 **Table 2: Excluded economic studies**

Study	Reason for exclusion
Abdollahian, Mehrnaz and Das, Tapas K (2015) A MDP model for breast and ovarian cancer intervention strategies for BRCA1/2 mutation carriers. IEEE journal of biomedical and health informatics 19(2): 720-7	- Only mentions cost / insufficient detail <i>Presents cost-optimal and QALY-optimal surgical and/or screening strategy. Focus on breast cancer surveillance, i.e., annual screening with mammography and magnetic resonance imaging.</i>
Akbari, M.R.; Gojska, N.; Narod, S.A. (2017) Coming of age in Canada: A study of population-based genetic testing for breast and ovarian cancer. Current Oncology 24(5): 282-283	- Population screening
Alblas, Maaïke, Peterse, Elisabeth F P, Du, Mengmeng et al. (2021) Cost-effectiveness of prophylactic hysterectomy in first-degree female relatives with Lynch syndrome of patients diagnosed with colorectal cancer in the United States: a microsimulation study. Cancer medicine 10(19): 6835-6844	- Population not in PICO
Alexander, Vinita M, Gordon, Alan N, Howard, David H et al. (2017) Outcomes and Cost Analysis of Surveillance Strategies After Initial Treatment for Women With Recurrent Ovarian Cancer. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 27(7): 1333-1342	- Population not in PICO <i>Recurrent ovarian cancer</i>
Armstrong, Amy, Otvos, Balint, Singh, Sareena et al. (2013) Evaluation of the cost of CA-125 measurement, physical exam,	- Population not in PICO <i>Recurrent ovarian cancer</i>

Ovarian cancer: identifying and managing familial and genetic risk, Supplement 2 – Economic literature DRAFT for Consultation (September 2023)

Study	Reason for exclusion
and imaging in the diagnosis of recurrent ovarian cancer. <i>Gynecologic oncology</i> 131(3): 503-7	
Arvai, Kristof, Horvath, Peter, Balla, Bernadett et al. (2014) Rapid and cost effective screening of breast and ovarian cancer genes using novel sequence capture method in clinical samples. <i>Familial cancer</i> 13(4): 583-9	- Only mentions cost / insufficient detail
Asphaug, Lars and Melberg, Hans Olav (2019) The Cost-Effectiveness of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer in Norway. <i>MDM policy & practice</i> 4(1): 2381468318821103	- Intervention not in PICO
Azardoost, H., Rahimi, F., Zeinalian, M. et al. (2021) Cost-effectiveness analysis of molecular screening to identify lynch syndrome in the patients with colorectal cancer. <i>International Journal of Cancer Management</i> 14(4): e108198	- Population not in PICO
Barzi, Afsaneh, Sadeghi, Sarmad, Kattan, Michael W et al. (2015) Comparative effectiveness of screening strategies for Lynch syndrome. <i>Journal of the National Cancer Institute</i> 107(4)	- Intervention not in PICO
Best, A.F.; Tucker, M.A.; Katki, H.A. (2017) Population-wide vs. carrier-probability-based BRCA1/2 mutation testing in the Washington Ashkenazi Study. <i>Cancer Research</i> 77(13supplement1)	- Conference abstract
Byfield, Stacey Dacosta, Wei, Helen, DuCharme, Mary et al. (2021) Economic impact of multigene panel testing for hereditary breast and ovarian cancer. <i>Journal of comparative effectiveness research</i> 10(3): 207-217	- Intervention not in PICO
Chandrasekaran, D. and Manchanda, R. (2018) Germline and somatic genetic testing in ovarian cancer patients. <i>BJOG: An International Journal of Obstetrics and Gynaecology</i> 125(11): 1460	- Commentary

Study	Reason for exclusion
<p>Chang, Yaojen, Near, Aimee M, Butler, Karin M et al. (2016) Economic Evaluation Alongside a Clinical Trial of Telephone Versus In-Person Genetic Counseling for BRCA1/2 Mutations in Geographically Underserved Areas. <i>Journal of oncology practice</i> 12(1): 59-13</p>	<p>- Population not in PICO <i><10% had a history of ovarian cancer, the rest personal history of breast cancer</i></p>
<p>Cheng, Li-Jen, Wong, Grace, Chay, Wen-Yee et al. (2021) Cost-effectiveness of olaparib maintenance therapy when used with and without restriction by BRCA1/2 mutation status for platinum-sensitive relapsed ovarian cancer. <i>Expert review of pharmacoeconomics & outcomes research</i> 21(3): 441-448</p>	<p>- Non-OECD country</p>
<p>Cheol, L.M., Jin, P.S., Seung, K.H. et al. (2021) A cost-utility analysis of the genetic test for Lynch syndrome in Korean women with gynecologic cancer. <i>Journal of Obstetrics and Gynaecology Research</i> 47(8): 2848-2849</p>	<p>- Conference abstract</p>
<p>Colling, Richard, Church, David N, Carmichael, Juliet et al. (2015) Screening for Lynch syndrome and referral to clinical genetics by selective mismatch repair protein immunohistochemistry testing: an audit and cost analysis. <i>Journal of clinical pathology</i> 68(12): 1036-9</p>	<p>- Population not in PICO</p>
<p>Corral, J., Pineda, M., Jimenez, C. et al. (2016) Cost analysis of the molecular screening and genetic diagnosis of lynch syndrome in catalonia (Spain). <i>Value in Health</i> 19(7): a614</p>	<p>- Conference abstract - Population not in PICO</p>
<p>Cunich, M., Schofield, D., Trainer, A. et al. (2017) Genbreastcamod: A microsimulation model of population-based genetic screening for hereditary breast and ovarian cancer. <i>Twin Research and Human Genetics</i> 20(5): 477</p>	<p>- Conference abstract</p>
<p>D'Andrea, Elvira, Marzuillo, Carolina, De Vito, Corrado et al. (2016) Which BRCA genetic testing programs are ready for implementation in health care? A systematic review of economic evaluations. <i>Genetics in medicine : official journal of the American</i></p>	<p>- Systematic review (all relevant primary studies included)</p>

Study	Reason for exclusion
College of Medical Genetics 18(12): 1171-1180	
D'Andrea, Elvira, Marzuillo, Carolina, Pelone, Ferruccio et al. (2015) Genetic testing and economic evaluations: a systematic review of the literature. <i>Epidemiologia e prevenzione</i> 39(4suppl1): 45-50	- Systematic review (all relevant primary studies included)
de Bock, G H, Vermeulen, K M, Jansen, L et al. (2013) Which screening strategy should be offered to women with BRCA1 or BRCA2 mutations? A simulation of comparative cost-effectiveness. <i>British journal of cancer</i> 108(8): 1579-86	- Population not in PICO
De Bock, G.H., Vermeulen, K.M., Jansen, L. et al. (2012) Tailored high-risk screening should be offered predominantly to women with BRCA1 or BRCA2 mutations: A simulation of comparative cost-effectiveness. <i>Current Oncology</i> 19(2): e87	- Conference abstract
Di Marco, Marco; D'Andrea, Elvira; Villari, Paolo (2019) Universal screening of Lynch syndrome is ready for implementation. <i>Genetics in medicine : official journal of the American College of Medical Genetics</i> 21(1): 254-255	- Commentary
Di Marco, Marco, D'Andrea, Elvira, Panic, Nikola et al. (2018) Which Lynch syndrome screening programs could be implemented in the "real world"? A systematic review of economic evaluations. <i>Genetics in medicine : official journal of the American College of Medical Genetics</i> 20(10): 1131-1144	- Population not in PICO <i>Most studies focused on newly diagnosed colorectal cancer patients</i>
Dillon, M., Jenkins, M.A., Buchanan, D.D. et al. (2019) The cost of identifying Lynch syndrome carriers in Australia. <i>Hereditary Cancer in Clinical Practice</i> 17(supplement2)	- Conference abstract
Dinh, Tuan A, Rosner, Benjamin I, Atwood, James C et al. (2011) Health benefits and cost-effectiveness of primary genetic screening for Lynch syndrome in the general population. <i>Cancer prevention research (Philadelphia, Pa.)</i> 4(1): 9-22	- Older than 10 years

Study	Reason for exclusion
Doherty, Jennifer; Bonadies, Danielle C; Matloff, Ellen T (2015) Testing for Hereditary Breast Cancer: Panel or Targeted Testing? Experience from a Clinical Cancer Genetics Practice. <i>Journal of genetic counseling</i> 24(4): 683-7	- Only mentions cost / insufficient detail
Drescher, Charles W, Hawley, Sarah, Thorpe, Jason D et al. (2012) Impact of screening test performance and cost on mortality reduction and cost-effectiveness of multimodal ovarian cancer screening. <i>Cancer prevention research (Philadelphia, Pa.)</i> 5(8): 1015-24	- Population screening
Drummey, A.B., Brown, J., Drury, L. et al. (2019) A cost-effectiveness analysis of universal genetic testing for common hereditary cancer mutations in women compared with family-history based testing. <i>Gynecologic Oncology</i> 153(3): e20	- Population screening
Erten, Mujde Z, Fernandez, Luca P, Ng, Hank K et al. (2016) Universal Versus Targeted Screening for Lynch Syndrome: Comparing Ascertainment and Costs Based on Clinical Experience. <i>Digestive diseases and sciences</i> 61(10): 2887-2895	- Population not in PICO
Esselen, Katharine M, Cronin, Angel M, Bixel, Kristin et al. (2016) Use of CA-125 Tests and Computed Tomographic Scans for Surveillance in Ovarian Cancer. <i>JAMA oncology</i> 2(11): 1427-1433	- Non-comparative study
Evans, Olivia; Gaba, Faiza; Manchanda, Ranjit (2020) Population-based genetic testing for Women's cancer prevention. <i>Best practice & research. Clinical obstetrics & gynaecology</i> 65: 139-153	- Population screening
Fakkert, I.E., Mensenkamp, A.R., Leter, E.M. et al. (2019) BRCA testing in ovarian tumors initiated by a pathologist: A pre-screen for germline testing and therapy choice. <i>European Journal of Human Genetics</i> 26(supplement1): 528-529	- Conference abstract
Ficarazzi, Filomena, Vecchi, Manuela, Ferrari, Maurizio et al. (2021) Towards	- Systematic review (all relevant primary studies included)

Study	Reason for exclusion
population-based genetic screenings for breast and ovarian cancer: A comprehensive review from economic evaluations to patient perspectives. <i>Breast (Edinburgh, Scotland)</i> 58: 121-129	
Foote, Jonathan R, Lopez-Acevedo, Micael, Buchanan, Adam H et al. (2017) Cost Comparison of Genetic Testing Strategies in Women With Epithelial Ovarian Cancer. <i>Journal of oncology practice</i> 13(2): e120-e129	- Intervention not in PICO
Gaba, F.M. and Manchanda, R. (2017) Genetic testing for gynaecological cancer. <i>Obstetrics, Gynaecology and Reproductive Medicine</i> 27(1): 29-31	- Systematic review (all relevant primary studies included)
Gallego, Carlos J, Shirts, Brian H, Bennette, Caroline S et al. (2015) Next-Generation Sequencing Panels for the Diagnosis of Colorectal Cancer and Polyposis Syndromes: A Cost-Effectiveness Analysis. <i>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</i> 33(18): 2084-91	- Population not in PICO
Gamble, Charlotte, Havrilesky, Laura J, Myers, Evan R et al. (2017) Cost Effectiveness of Risk-Reducing Mastectomy versus Surveillance in BRCA Mutation Carriers with a History of Ovarian Cancer. <i>Annals of surgical oncology</i> 24(11): 3116-3123	- Population not in PICO
Gausachs, Mireia, Mur, Pilar, Corral, Julieta et al. (2012) MLH1 promoter hypermethylation in the analytical algorithm of Lynch syndrome: a cost-effectiveness study. <i>European journal of human genetics : EJHG</i> 20(7): 762-8	- Population not in PICO
George, Angela (2015) UK BRCA mutation testing in patients with ovarian cancer. <i>British journal of cancer</i> 113suppl1: 17-21	- Only mentions cost / insufficient detail
George, Angela, Riddell, Daniel, Seal, Sheila et al. (2016) Implementing rapid, robust, cost-effective, patient-centred, routine genetic testing in ovarian cancer patients. <i>Scientific reports</i> 6: 29506	- Service evaluation <i>Insufficient detail and only discusses potential resource/cost implications</i>

Study	Reason for exclusion
Gogollari, A., Sroczynski, G., Oberaigner, W. et al. (2018) IS SCREENING FOR OVARIAN CANCER EFFECTIVE AND COST EFFECTIVE IN AUSTRIA? A MODEL-BASED ECONOMIC EVALUATION. Value in Health 21(supplement3): 256-s257	- Conference abstract
Gonzalez, Rafael, Havrilesky, Laura J, Myers, Evan R et al. (2020) Cost-effectiveness analysis comparing "PARP inhibitors-for-all" to the biomarker-directed use of PARP inhibitor maintenance therapy for newly diagnosed advanced stage ovarian cancer. Gynecologic oncology 159(2): 483-490	- Intervention not in PICO
Gonzalez-Dominguez, A., Moya, C., Simon, S. et al. (2018) COST-UTILITY ANALYSIS OF THE GERMLINE BRCA TESTING IN WOMEN WITH EPITHELIAL OVARIAN CANCER WITHOUT FAMILY HISTORY IN SPAIN. Value in Health 21(supplement3): 47	- Conference abstract
Gorski, Justin W, Quattrone, McKell, van Nagell, John R et al. (2020) Assessing the Costs of Screening for Ovarian Cancer in the United States: An Evolving Analysis. Diagnostics (Basel, Switzerland) 10(2)	- Population screening
Gould-Suarez, Milena, El-Serag, Hashem B, Musher, Benjamin et al. (2014) Cost-effectiveness and diagnostic effectiveness analyses of multiple algorithms for the diagnosis of Lynch syndrome. Digestive diseases and sciences 59(12): 2913-26	- Population not in PICO <i>People with colorectal cancer</i>
Goverde, Anne, Spaander, Manon Cw, van Doorn, Helena C et al. (2016) Cost-effectiveness of routine screening for Lynch syndrome in endometrial cancer patients up to 70years of age. Gynecologic oncology 143(3): 453-459	- Population not in PICO
Grann, V. and Ashby-Thompson, M. (2013) Role of genetic testing for screening and prevention for ovarian cancer. JAMA Internal Medicine 173(2): 103-104	- Commentary

Study	Reason for exclusion
<p>Green, P.J. and Shaw, E. (2021) Systematic review of the best combination and sequence of tests to detect lynch syndrome in colorectal adenocarcinoma samples. <i>Journal of Pathology</i> 255(suppl1): 24</p>	<p>- Conference abstract</p>
<p>Grosse, S.D. (2014) Economic analyses of genetic tests in personalized medicine: Clinical utility first, then cost utility. <i>Genetics in Medicine</i> 16(3): 225-227</p>	<p>- Systematic review (all relevant primary studies included)</p>
<p>Grosse, S.D. and Khoury, M.J. (2016) Epidemiology matters: Peering inside the "black box" in economic evaluations of genetic testing. <i>Genetics in Medicine</i> 18(10): 963-965</p>	<p>- Commentary</p>
<p>Grosse, Scott D (2015) When is Genomic Testing Cost-Effective? Testing for Lynch Syndrome in Patients with Newly-Diagnosed Colorectal Cancer and Their Relatives. <i>Healthcare (Basel, Switzerland)</i> 3(4): 860-78</p>	<p>- Population not in PICO</p>
<p>Grosse, Scott D, Palomaki, Glenn E, Mvundura, Mercy et al. (2015) The cost-effectiveness of routine testing for Lynch syndrome in newly diagnosed patients with colorectal cancer in the United States: corrected estimates. <i>Genetics in medicine : official journal of the American College of Medical Genetics</i> 17(6): 510-1</p>	<p>- Population not in PICO</p>
<p>Gudgeon, James M, Belnap, Thomas W, Williams, Janet L et al. (2013) Impact of age cutoffs on a lynch syndrome screening program. <i>Journal of oncology practice</i> 9(4): 175-9</p>	<p>- Population not in PICO</p>
<p>Guzauskas, Gregory F, Garbett, Shawn, Zhou, Zilu et al. (2020) Cost-effectiveness of Population-Wide Genomic Screening for Hereditary Breast and Ovarian Cancer in the United States. <i>JAMA network open</i> 3(10): e2022874</p>	<p>- Population screening</p>
<p>Harmsen, Marline G, Arts-de Jong, Marieke, Hoogerbrugge, Nicoline et al. (2015) Early salpingectomy (TUbectomy) with delayed</p>	<p>- Protocol</p>

Study	Reason for exclusion
oophorectomy to improve quality of life as alternative for risk-reducing salpingo-oophorectomy in BRCA1/2 mutation carriers (TUBA study): a prospective non-randomised multicentre study. BMC cancer 15: 593	
Hart, Gregory R, Nartowt, Bradley J, Muhammad, Wazir et al. (2019) Stratifying Ovarian Cancer Risk Using Personal Health Data. Frontiers in big data 2: 24	- Only mentions cost / insufficient detail
Havrilesky, Laura J, Moss, Haley A, Chino, Junzo et al. (2017) Mortality reduction and cost-effectiveness of performing hysterectomy at the time of risk-reducing salpingo-oophorectomy for prophylaxis against serous/serous-like uterine cancers in BRCA1 mutation carriers. Gynecologic oncology 145(3): 549-554	- Population not in PICO <i>Risk reducing hysterectomy against serous/serous-like uterine cancers</i>
Holland, Margaret L; Huston, Alissa; Noyes, Katia (2009) Cost-effectiveness of testing for breast cancer susceptibility genes. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 12(2): 207-16	- Older than 10 years
Hong, N.L., Nofech-Mozes, S., Olkhov-Mitsel, E. et al. (2019) Budget impact analysis of reflex BRCA tumor testing compared to counselling-directed BRCA testing for high grade serous Mullerian cancer. Modern Pathology 32(3)	- Conference abstract
Horwitz, J., Geurts, J., Einstein, M. et al. (2010) The cost of detecting lynch syndrome by microsatellite instability testing in community practice. American Journal of Gastroenterology 105(suppl1): 547	- Conference abstract
Hoskins, P., Ecclestone, A., Hurry, M. et al. (2018) Cascade BRCA germline mutation (BGM) testing of women with breast (BC) or epithelial ovarian cancer (EOC) and their families with subsequent risk reducing surgery (RRS): A Canadian economics model. Annals of Oncology 29(supplement8)	- Conference abstract

Study	Reason for exclusion
Hynes, Jaclyn, MacMillan, Andree, Fernandez, Sara et al. (2020) Group plus "mini" individual pre-test genetic counselling sessions for hereditary cancer shorten provider time and improve patient satisfaction. <i>Hereditary cancer in clinical practice</i> 18: 3	- Nothing relevant on the cost-effectiveness
Kahn, Ryan Matthew, Ahsan, Muhammad Danyal, Chapman-Davis, Eloise et al. (2023) Barriers to completion of cascade genetic testing: how can we improve the uptake of testing for hereditary breast and ovarian cancer syndrome?. <i>Familial cancer</i> 22(2): 127-133	- Nothing relevant on the cost-effectiveness
Kaldate, Rajesh, Huston, Alissa, McCoy, Heidi et al. (2014) Cost effectiveness analysis of genetic testing for breast and ovarian cancer susceptibility genes: BRCA1 and BRCA2. <i>The breast journal</i> 20(3): 325-6	- Commentary
Kang, Y.-J., Caruana, M., McLoughlin, K. et al. (2021) The cost-effectiveness of tailored colonoscopic surveillance strategies for Lynch syndrome carriers. <i>Asia-Pacific Journal of Clinical Oncology</i> 17(suppl5): 55-56	- Conference abstract
Kang, Y., Caruana, M., Mcloughlin, K. et al. (2021) Should different surveillance options be offered to Lynch syndrome carriers with different mismatch repair gene mutations? Predicted impact and cost-effectiveness of tailored colonoscopic surveillance strategies in people with Lynch syndrome. <i>Journal of Gastroenterology and Hepatology</i> 36(suppl3): 15	- Conference abstract
Kang, Yoon-Jung, Killen, James, Caruana, Michael et al. (2020) The predicted impact and cost-effectiveness of systematic testing of people with incident colorectal cancer for Lynch syndrome. <i>The Medical journal of Australia</i> 212(2): 72-81	- Population not in PICO
Kastrinos, F. and Steyerberg, E.W. (2015) Family matters in lynch syndrome. <i>Journal of the National Cancer Institute</i> 107(4)	- Commentary

Study	Reason for exclusion
Kearns, Ben, Chilcott, Jim, Whyte, Sophie et al. (2016) Cost-effectiveness of screening for ovarian cancer amongst postmenopausal women: a model-based economic evaluation. BMC medicine 14(1): 200	- Population screening
Kerr, Shona M, Cowan, Emma, Klaric, Lucija et al. (2023) Clinical case study meets population cohort: identification of a BRCA1 pathogenic founder variant in Orcadians. European journal of human genetics : EJHG	- Only mentions cost / insufficient detail
Koldehoff, Andreas, Danner, Marion, Civello, Daniele et al. (2021) Cost-Effectiveness of Targeted Genetic Testing for Breast and Ovarian Cancer: A Systematic Review. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 24(2): 303-312	- Systematic review (all relevant primary studies included)
Kurian, A.W.; Bernhisel, R.; Stefanick, M.L. (2020) Pathogenic Variants in Breast Cancer Susceptibility Genes in Older Women - Reply. JAMA - Journal of the American Medical Association 324(4): 397-398	- Commentary
Kwon, J.S., Tinker, A., Santos, J. et al. (2021) Germline testing and somatic tumor testing for BRCA1/2pathogenic variants in ovarian cancer: What is the optimal sequence of testing?. Journal of Clinical Oncology 39(15suppl)	- Conference abstract
Kwon, J.S., Tinker, A.V., Karsan, A. et al. (2019) Costs and benefits of tumor testing for BRCA mutations in high-grade serous ovarian cancer as a companion diagnostic for PARP inhibitor treatment. Gynecologic Oncology 154(supplement1): 177	- Conference abstract
Kwon, J.S., Tinker, A.V., Karsan, A. et al. (2019) Costs and benefits of tumor testing for BRCA mutations in high-grade serous ovarian cancer as a triage for confirmatory genetic testing. Gynecologic Oncology 154(supplement1): 5	- Conference abstract

Study	Reason for exclusion
Kwon, Janice S (2017) Cost-effectiveness of Ovarian Cancer Prevention Strategies. Clinical obstetrics and gynecology 60(4): 780-788	- Systematic review (all relevant primary studies included)
Kwon, J. S., Tinker, A., Pansegrau, G., McAlpine, J., Housty, M., McCullum, M., & Gilks, C. B., (2013) Prophylactic salpingectomy and delayed oophorectomy as an alternative for BRCA mutation carriers, Obstetrics & Gynecology, 121, 14-24	- Costs were reported from a societal perspective only (healthcare costs only could not be derived)
Ladabaum, U., Wang, G., Terdiman, J.P. et al. (2010) Universal colorectal tumor testing to identify families with lynch syndrome could be highly effective and cost-effective: Family participation holds the key. Gastroenterology 138(5suppl1): 295	- Conference abstract
Ladabaum, Uri, Wang, Grace, Terdiman, Jonathan et al. (2011) Strategies to identify the Lynch syndrome among patients with colorectal cancer: a cost-effectiveness analysis. Annals of internal medicine 155(2): 69-79	- Older than 10 years
Leenen, Celine H M, Goverde, Anne, de Bekker-Grob, Esther W et al. (2016) Cost-effectiveness of routine screening for Lynch syndrome in colorectal cancer patients up to 70 years of age. Genetics in medicine : official journal of the American College of Medical Genetics 18(10): 966-73	- Population not in PICO
Leung, John Hang, Lang, Hui-Chu, Wang, Shyh-Yau et al. (2021) Cost-effectiveness analysis of olaparib and niraparib as maintenance therapy for women with recurrent platinum-sensitive ovarian cancer. Expert review of pharmacoeconomics & outcomes research: 1-8	- Non-OECD country
Lew, Jie-Bin, Feletto, Eleanor, Wade, Stephen et al. (2019) Benefits, harms and cost-effectiveness of cancer screening in Australia: an overview of modelling estimates. Public health research & practice 29(2)	- Nothing relevant on the cost-effectiveness

Study	Reason for exclusion
Li, Y., Arellano, A.R., Bare, L.A. et al. (2018) Cost-effectiveness of genetic testing with a hereditary cancer panel in women at risk of hereditary breast cancer. <i>Cancer Research</i> 78(4supplement1)	- Conference abstract
Li, Yonghong, Arellano, Andre R, Bare, Lance A et al. (2017) A Multigene Test Could Cost-Effectively Help Extend Life Expectancy for Women at Risk of Hereditary Breast Cancer. <i>Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research</i> 20(4): 547-555	- Population not in PICO
Lim, S., Moss, H., Havrilesky, L. et al. (2021) A novel, out-of-pocket, cost-effectiveness analysis comparing a frontline niraparib-for-all to a biomarker-based strategy in patients with advanced ovarian cancer. <i>Gynecologic Oncology</i> 162(supplement1): 77	- Conference abstract
Long, Elisa F and Ganz, Patricia A (2015) Cost-effectiveness of Universal BRCA1/2 Screening: Evidence-Based Decision Making. <i>JAMA oncology</i> 1(9): 1217-8	- Population screening
Lourencao, M., Simoes Correa Galendi, J., Galvao, H.D.C.R. et al. (2022) Cost-Effectiveness of BRCA 1/2 Genetic Test and Preventive Strategies: Using Real-World Data From an Upper-Middle Income Country. <i>Frontiers in Oncology</i> 12: 951310	- Non-OECD country
Manchanda, R. (2015) Brca testing in high-risk populations. <i>Clinical Cancer Research</i> 21(16supplement1)	- Conference abstract
Manchanda, R. and Legood, R. (2018) Population based germline testing for primary cancer prevention. <i>Oncotarget</i> 9(69): 33062-33063	- Commentary
Manchanda, R., Sun, L., Patel, S. et al. (2019) Global economic evaluation of population-based BRCA1/BRCA2 mutation testing. <i>International Journal of Gynecological Cancer</i> 29(supplement3): a6-a7	- Conference abstract

Study	Reason for exclusion
Manchanda, Ranjit and Gaba, Faiza (2018) Population Based Testing for Primary Prevention: A Systematic Review. <i>Cancers</i> 10(11)	- Systematic review (all relevant primary studies included)
Manchanda, Ranjit and Jacobs, Ian (2016) Genetic screening for gynecological cancer: where are we heading?. <i>Future oncology</i> (London, England) 12(2): 207-20	- Systematic review (all relevant primary studies included)
Manchanda, Ranjit and Menon, Usha (2018) Setting the Threshold for Surgical Prevention in Women at Increased Risk of Ovarian Cancer. <i>International journal of gynecological cancer : official journal of the International Gynecological Cancer Society</i> 28(1): 34-42	- Systematic review (all relevant primary studies included)
Manchanda, Ranjit, Patel, Shreeya, Gordeev, Vladimir S et al. (2018) Cost-effectiveness of Population-Based BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 Mutation Testing in Unselected General Population Women. <i>Journal of the National Cancer Institute</i> 110(7): 714-725	- Population screening
Manchanda, Ranjit, Sun, Li, Patel, Shreeya et al. (2020) Economic Evaluation of Population-Based BRCA1/BRCA2 Mutation Testing across Multiple Countries and Health Systems. <i>Cancers</i> 12(7)	- Population screening
Marino, P., Touzani, R., Perrier, L. et al. (2018) Cost of cancer diagnosis using next-generation sequencing targeted gene panels in routine practice: A nationwide French study. <i>European Journal of Human Genetics</i> 26(3): 314-323	- Non-comparative study
Mauer, Caitlin B, Reys, Brian D, Hall, Reece E et al. (2021) Downstream Revenue Generated by a Cancer Genetic Counselor. <i>JCO oncology practice</i> 17(9): e1394-e1402	- Intervention not in PICO
Menon, Usha, McGuire, Alistair J, Raikou, Maria et al. (2017) The cost-effectiveness of screening for ovarian cancer: results from the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). <i>British journal of cancer</i> 117(5): 619-627	- Population screening

Study	Reason for exclusion
Meshkani, Zahra, Aboutorabi, Ali, Moradi, Najmeh et al. (2021) Population or family history based BRCA gene tests of breast cancer? A systematic review of economic evaluations. <i>Hereditary cancer in clinical practice</i> 19(1): 35	- Systematic review (all relevant primary studies included)
Michaan, N., Lashno, M., Safra, T. et al. (2019) Whole population BRCA screening is cost effective in Israel, even with varying prevalence of BRCA mutation. <i>Gynecologic Oncology</i> 154(supplement1): 224-225	- Conference abstract
Michaan, Nadav, Leshno, Moshe, Safra, Tamar et al. (2021) Cost Effectiveness of Whole Population BRCA Genetic Screening for Cancer Prevention in Israel. <i>Cancer prevention research (Philadelphia, Pa.)</i> 14(4): 455-462	- Population screening
Miquel-Cases, Anna, Steuten, Lotte M G, Retel, Valesca P et al. (2015) Early stage cost-effectiveness analysis of a BRCA1-like test to detect triple negative breast cancers responsive to high dose alkylating chemotherapy. <i>Breast (Edinburgh, Scotland)</i> 24(4): 397-405	- Population not in PICO
Moss, H., Myers, E., Berchuck, A. et al. (2017) Cost-effectiveness of ovarian cancer screening: An analysis of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) from a U.S. Health system perspective. <i>Journal of Clinical Oncology</i> 35(15supplement1)	- Conference abstract
Moss, Haley A, Berchuck, Andrew, Neely, Megan L et al. (2018) Estimating Cost-effectiveness of a Multimodal Ovarian Cancer Screening Program in the United States: Secondary Analysis of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). <i>JAMA oncology</i> 4(2): 190-195	- Population screening
Muhlberger, N., Sroczynski, G., Gogollari, A. et al. (2017) Cost-effectiveness of breast cancer screening and prevention-a systematic review of decision-analytic models for European settings. <i>International</i>	- Conference abstract

Study	Reason for exclusion
Journal of Gynecological Cancer 27(supplement4): 365	
Murgia, F., Fiorito, M.A., Donvito, V.R. et al. (2018) Laparoscopic bilateral salpingo-oophorectomy in brcamut: A single centre cost and time effectiveness analysis. International Journal of Gynecological Cancer 28(supplement2): 660	- Conference abstract
Mvundura, Mercy, Grosse, Scott D, Hampel, Heather et al. (2010) The cost-effectiveness of genetic testing strategies for Lynch syndrome among newly diagnosed patients with colorectal cancer. Genetics in medicine : official journal of the American College of Medical Genetics 12(2): 93-104	- Older than 10 years
Naumann, R Wendel and Brown, Jubilee (2018) Ovarian cancer screening with the Risk of Ovarian Cancer Algorithm (ROCA): Good, bad, or just expensive?. Gynecologic oncology 149(1): 117-120	- Population screening
Ofshateyn, Asya, Jiang, Boxiang, Bingmer, Katherine et al. (2020) Prophylactic Gynecologic Surgery at Time of Colectomy Benefits Women with Lynch Syndrome and Colon Cancer: A Markov Cost-Effectiveness Analysis. Diseases of the colon and rectum 63(10): 1393-1402	- Population not in PICO
Ozanne, E.M., Cipriano, L., Cameron, M. et al. (2009) Cost-effectiveness of genetic testing for BRCA1 and BRCA2 mutations. Cancer Research 69(2suppl)	- Conference abstract
Paez, M.C., Riggi, M.C., Gogorza, S.J. et al. (2018) Molecular test for BRCA 1 and 2: Hereditary breast and ovarian cancer syndrome. Analysis of cost effectiveness of its implementation. Cancer Research 78(4supplement1)	- Conference abstract
Pastorino, R., Michelazzo, M.B., Tognetto, A. et al. (2017) Screening pathways for Lynch syndrome: A systematic review of the existing pathways and a cost-effectiveness analysis in Italy. Familial Cancer 16(1supplement1): 131-s132	- Conference abstract

Study	Reason for exclusion
<p>Pastorino, Roberta, Basile, Michele, Tognetto, Alessia et al. (2020) Cost-effectiveness analysis of genetic diagnostic strategies for Lynch syndrome in Italy. <i>PLoS one</i> 15(7): e0235038</p>	<p>- Intervention not in PICO</p>
<p>Penn, C.; Wong, M.; Walsh, C.S. (2020) Cost-effectiveness of various maintenance therapies based on mutation status following first-line treatment of primary epithelial ovarian cancer in the United States. <i>Journal of Clinical Oncology</i> 38(15)</p>	<p>- Conference abstract</p>
<p>Penn, C.A., Wong, M.S., Lee, J. et al. (2020) Cost-minimization analysis of germline and somatic testing strategies for BRCA mutations in women with newly diagnosed epithelial ovarian cancer. <i>Gynecologic Oncology</i> 159(supplement1): 127</p>	<p>- Conference abstract</p>
<p>Penn, Courtney A; Wong, Melissa S; Walsh, Christine S (2020) Cost-effectiveness of Maintenance Therapy Based on Molecular Classification Following Treatment of Primary Epithelial Ovarian Cancer in the United States. <i>JAMA network open</i> 3(12): e2028620</p>	<p>- Intervention not in PICO</p>
<p>Petelin, L., Hossack, L., Trainer, A. et al. (2017) Cost-effectiveness of cancer risk management for BRCA1/2 carriers: Evaluation of the annual review program. <i>Twin Research and Human Genetics</i> 20(5): 478</p>	<p>- Conference abstract</p>
<p>Petelin, L., Liew, D., Mitchell, G. et al. (2018) An economic evaluation of a familial cancer risk management program for BRCA mutation carriers: An Australian perspective. <i>Value in Health</i> 21(supplement1): 1-s2</p>	<p>- Conference abstract</p>
<p>Petelin, L., Mitchell, G., Liew, D. et al. (2021) Economic evaluation of breast and ovarian polygenic risk scores for women with a pathogenic variant. <i>Asia-Pacific Journal of Clinical Oncology</i> 17(suppl5): 52</p>	<p>- Conference abstract</p>

Study	Reason for exclusion
<p>Petelin, L., Salmon, L., Mitchell, G. et al. (2021) Modelling patient and healthcare services outcomes from applying polygenic risk scores for breast and ovarian cancer in pathogenic variant carriers. <i>Twin Research and Human Genetics</i> 24(5): 297</p>	<p>- Conference abstract</p>
<p>Petelin, Lara, Hossack, Lucinda, Shanahan, Mary et al. (2020) Cost-effectiveness of long-term clinical management of BRCA pathogenic variant carriers. <i>Genetics in medicine : official journal of the American College of Medical Genetics</i> 22(5): 831-839</p>	<p>- Intervention not in PICO</p>
<p>Petelin, Lara, Trainer, Alison H, Mitchell, Gillian et al. (2018) Cost-effectiveness and comparative effectiveness of cancer risk management strategies in BRCA1/2 mutation carriers: a systematic review. <i>Genetics in medicine : official journal of the American College of Medical Genetics</i> 20(10): 1145-1156</p>	<p>- Systematic review (all relevant primary studies included)</p>
<p>Peterse, Elisabeth F P, Naber, Steffie K, Daly, Corinne et al. (2020) Cost-effectiveness of Active Identification and Subsequent Colonoscopy Surveillance of Lynch Syndrome Cases. <i>Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association</i> 18(12): 2760-2767e12</p>	<p>- Population not in PICO</p>
<p>Pruneri, G., De Braud, F., Sapino, A. et al. (2021) Next-Generation Sequencing in Clinical Practice: Is It a Cost-Saving Alternative to a Single-Gene Testing Approach?. <i>Pharmacoeconomics - Open</i> 5(2): 285-298</p>	<p>- Population not in PICO</p>
<p>Randy Vogenberg, F. (2017) Economic impact of using tests to guide the treatment of patients with ovarian cancer. <i>American Health and Drug Benefits</i> 10(7): 359</p>	<p>- Intervention not in PICO</p>
<p>Rettenmaier, N B, Rettenmaier, C R, Wojciechowski, T et al. (2010) The utility and cost of routine follow-up procedures in the surveillance of ovarian and primary peritoneal carcinoma: a 16-year institutional</p>	<p>- Population not in PICO</p>

Study	Reason for exclusion
review. British journal of cancer 103(11): 1657-62	
Romero Prada, M.E., Roa Cardenas, N.C., Vasquez Melo, E.C. et al. (2017) Economic impact analysis of brca1 and BRCA2 genetic tests in women with advanced stage ovarian cancer in the Colombian context. Value in Health 20(5): a240	- Conference abstract
Roth, Rachel M, Hampel, Heather, Arnold, Christina A et al. (2015) A modified Lynch syndrome screening algorithm in colon cancer: BRAF immunohistochemistry is efficacious and cost beneficial. American journal of clinical pathology 143(3): 336-43	- Population not in PICO
Rubinstein, Wendy S, Jiang, Hongmei, Dellefave, Lisa et al. (2009) Cost-effectiveness of population-based BRCA1/2 testing and ovarian cancer prevention for Ashkenazi Jews: a call for dialogue. Genetics in medicine : official journal of the American College of Medical Genetics 11(9): 629-39	- Older than 10 years
Salikhanov, Islam, Heinimann, Karl, Chappuis, Pierre et al. (2021) Swiss cost-effectiveness analysis of universal screening for Lynch syndrome of patients with colorectal cancer followed by cascade genetic testing of relatives. Journal of medical genetics	- Population not in PICO
Sarki, Mahesh, Ming, Chang, Aceti, Monica et al. (2022) Relatives from Hereditary Breast and Ovarian Cancer and Lynch Syndrome Families Forgoing Genetic Testing: Findings from the Swiss CASCADE Cohort. Journal of personalized medicine 12(10)	- Nothing relevant on the cost-effectiveness
Schrauder, Michael G, Brunel-Geuder, Lisa, Haberle, Lothar et al. (2019) Cost effectiveness of bilateral risk-reducing mastectomy and salpingo-oophorectomy. European journal of medical research 24(1): 32	- Cost analysis
Schrauder, Michael G, Brunel-Geuder, Lisa, Haberle, Lothar et al. (2017) Cost-	- Cost analysis

Study	Reason for exclusion
effectiveness of risk-reducing surgeries in preventing hereditary breast and ovarian cancer. <i>Breast (Edinburgh, Scotland)</i> 32: 186-191	
Schwartz, Marc D, Heiddis B, Valdimarsdottir, Beth N. Peshkin, Jeanne Mandelblatt, Rachel Nusbaum, An-Tsun Huang, Yaojen Chang et al. (2014) Randomized noninferiority trial of telephone versus in-person genetic counseling for hereditary breast and ovarian cancer. <i>Journal of Clinical Oncology</i> 32 (7): 618-626	- US study
Secord, Angeles Alvarez, Barnett, Jason Cory, Ledermann, Jonathan A et al. (2013) Cost-effectiveness of BRCA1 and BRCA2 mutation testing to target PARP inhibitor use in platinum-sensitive recurrent ovarian cancer. <i>International journal of gynecological cancer : official journal of the International Gynecological Cancer Society</i> 23(5): 846-52	- Intervention not in PICO
Senter, L, O'Connor, M, Oriyo, F et al. (2014) Linking distant relatives with BRCA gene mutations: potential for cost savings. <i>Clinical genetics</i> 85(1): 54-8	- Population not in PICO
Severin, Franziska, Stollenwerk, Bjorn, Holinski-Feder, Elke et al. (2015) Economic evaluation of genetic screening for Lynch syndrome in Germany. <i>Genetics in medicine : official journal of the American College of Medical Genetics</i> 17(10): 765-73	- Population not in PICO <i>People with colorectal cancer</i>
Shin, W. and Lim, M. (2019) Cost effectiveness analysis of risk reducing salpin-goophorectomy(RRSO)in preventing hereditary ovarian cancer. <i>Journal of Obstetrics and Gynaecology Research</i> 45(8): 1657	- Conference abstract
Sie, A S, Mensenkamp, A R, Adang, E M M et al. (2014) Fourfold increased detection of Lynch syndrome by raising age limit for tumour genetic testing from 50 to 70 years is cost-effective. <i>Annals of oncology : official journal of the European Society for Medical Oncology</i> 25(10): 2001-2007	- Population not in PICO

Study	Reason for exclusion
Simmons, D., Bhalla, J., Stone, R. et al. (2021) Clinical outcomes and cost associated with HRD biomarker guided first line maintenance therapy in advanced ovarian cancer. <i>Gynecologic Oncology</i> 162(supplement1): 111-s112	- Conference abstract
Simmons, D., Bhalla, J., Stone, R. et al. (2020) Cost of HRD biomarker-guided therapy in advanced ovarian cancer. <i>Journal of Managed Care and Specialty Pharmacy</i> 26(10asuppl): 28	- Conference abstract
Simoes Correa Galendi, Julia, Kautz-Freimuth, Sibylle, Stock, Stephanie et al. (2022) Uptake Rates of Risk-Reducing Surgeries for Women at Increased Risk of Hereditary Breast and Ovarian Cancer Applied to Cost-Effectiveness Analyses: A Scoping Systematic Review. <i>Cancers</i> 14(7)	- Nothing relevant on the cost-effectiveness
Simoes Correa Galendi, Julia, Vennedey, Vera, Kentenich, Hannah et al. (2021) Data on Utility in Cost-Utility Analyses of Genetic Screen-and-Treat Strategies for Breast and Ovarian Cancer. <i>Cancers</i> 13(19)	- Nothing relevant on the cost-effectiveness
Simoes Correa-Galendi, Julia, Del Pilar Estevez Diz, Maria, Stock, Stephanie et al. (2021) Economic Modelling of Screen-and-Treat Strategies for Brazilian Women at Risk of Hereditary Breast and Ovarian Cancer. <i>Applied health economics and health policy</i> 19(1): 97-109	- Non-OECD country
Slade, Ingrid, Hanson, Helen, George, Angela et al. (2016) A cost analysis of a cancer genetic service model in the UK. <i>Journal of community genetics</i> 7(3): 185-94	- Non-comparative study
Snowsill, T. (2020) Economic considerations for healthcare guidelines for gynaecological cancer in Lynch syndrome. <i>Familial Cancer</i> 19(1): 80	- Conference abstract
Snowsill, Tristan M; Ryan, Neil A J; Crosbie, Emma J (2020) Cost-Effectiveness of the Manchester Approach to Identifying Lynch Syndrome in Women with Endometrial Cancer. <i>Journal of clinical medicine</i> 9(6)	- Population not in PICO

Study	Reason for exclusion
Snowsill, Tristan M, Ryan, Neil A J, Crosbie, Emma J et al. (2019) Cost-effectiveness analysis of reflex testing for Lynch syndrome in women with endometrial cancer in the UK setting. PloS one 14(8): e0221419	- Population not in PICO
Snowsill, Tristan, Huxley, Nicola, Hoyle, Martin et al. (2014) A systematic review and economic evaluation of diagnostic strategies for Lynch syndrome. Health technology assessment (Winchester, England) 18(58): 1-406	- Population not in PICO
Snowsill, Tristan, Huxley, Nicola, Hoyle, Martin et al. (2015) A model-based assessment of the cost-utility of strategies to identify Lynch syndrome in early-onset colorectal cancer patients. BMC cancer 15: 313	- Population not in PICO
Sroczyński, G., Gogollari, A., Kuhne, F. et al. (2018) ECONOMIC EVALUATION OF SCREENING AND PREVENTION STRATEGIES FOR OVARIAN CANCER: A SYSTEMATIC REVIEW. Value in Health 21(supplement3): 256	- Conference abstract
Sroczyński, G., Gogollari, A., Kuhne, F. et al. (2017) A systematic review on cost-effectiveness of early detection and prevention strategies for ovarian cancer. International Journal of Gynecological Cancer 27(supplement4): 542	- Conference abstract
Sroczyński, Gaby, Gogollari, Artemisa, Kuehne, Felicitas et al. (2020) A Systematic Review on Cost-effectiveness Studies Evaluating Ovarian Cancer Early Detection and Prevention Strategies. Cancer prevention research (Philadelphia, Pa.) 13(5): 429-442	- Systematic review (all relevant primary studies included)
Subramaniam, Akila, Einerson, Brett D, Blanchard, Christina T et al. (2019) The cost-effectiveness of opportunistic salpingectomy versus standard tubal ligation at the time of cesarean delivery for ovarian cancer risk reduction. Gynecologic oncology 152(1): 127-132	- Population not in PICO

Study	Reason for exclusion
Sun, Li, Brentnall, Adam, Patel, Shreeya et al. (2019) A Cost-effectiveness Analysis of Multigene Testing for All Patients With Breast Cancer. <i>JAMA oncology</i>	- Population not in PICO
Tai, R W Melissa; Choi, Stephanie K Y; Coyte, Peter C (2018) The Cost-Effectiveness of Salpingectomies for Family Planning in the Prevention of Ovarian Cancer. <i>Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC</i> 40(3): 317-327	- Not available
Teppala, Srinivas, Hodgkinson, Brent, Hayes, Sandi et al. (2023) A review of the cost-effectiveness of genetic testing for germline variants in familial cancer. <i>Journal of medical economics</i> 26(1): 19-33	- Systematic review (all relevant primary studies included)
Tjelle, TE, Torkilseng, EB, Movik, E et al. (2018) Diagnostic accuracy, clinical effectiveness and budget impact of screening BRCA1/2 mutation carriers by MRI. <i>A health technology assessment.</i>	- Intervention not in PICO
Venkatesh, Kartik K; Clark, Leslie H; Stamilio, David M (2019) Cost-effectiveness of opportunistic salpingectomy vs tubal ligation at the time of cesarean delivery. <i>American journal of obstetrics and gynecology</i> 220(1): 106e1-106e10	- Population not in PICO
Wallbillich, J J, Forde, B, Havrilesky, L J et al. (2016) A personalized paradigm in the treatment of platinum-resistant ovarian cancer - A cost utility analysis of genomic-based versus cytotoxic therapy. <i>Gynecologic oncology</i> 142(1): 144-149	- Intervention not in PICO
Wang, Grace, Kuppermann, Miriam, Kim, Benjamin et al. (2012) Influence of patient preferences on the cost-effectiveness of screening for Lynch syndrome. <i>The American journal of managed care</i> 18(5): e179-85	- Duplicate
Wei, Xia, Oxley, Samuel, Sideris, Michail et al. (2022) Cost-Effectiveness of Risk-Reducing Surgery for Breast and Ovarian	- Systematic review (all relevant primary studies included)

Study	Reason for exclusion
Cancer Prevention: A Systematic Review. <i>Cancers</i> 14(24)	
Wright, Jason D, Silver, Elisabeth R, Tan, Sarah Xinhui et al. (2021) Cost-effectiveness Analysis of Genotype-Specific Surveillance and Preventive Strategies for Gynecologic Cancers Among Women With Lynch Syndrome. <i>JAMA network open</i> 4(9): e2123616	- Population not in PICO <i>Lynch syndrome associated cancers, such as colorectal, endometrial and ovarian cancers, including surveillance and risk reducing strategies</i>
Yang, Kathleen Y, Caughey, Aaron B, Little, Sarah E et al. (2011) A cost-effectiveness analysis of prophylactic surgery versus gynecologic surveillance for women from hereditary non-polyposis colorectal cancer (HNPCC) Families. <i>Familial cancer</i> 10(3): 535-43	- Older than 10 years
Zhu, J., Singh, V., Gershkovich, P. et al. (2021) COST-EFFECTIVENESS ANALYSIS OF SCREENING STRATEGIES FOR LYNCH SYNDROME UNDER DIFFERENT SYSTEMS APPROACHES. <i>Gastroenterology</i> 160(6supplement): 607	- Conference abstract

1 References to included economic studies

Bommer, C., Lupatsch, J., Burki, N., et al., Cost-utility analysis of risk-reducing strategies to prevent breast and ovarian cancer in BRCA-mutation carriers in Switzerland, *The European journal of health economics, HEPAC: health economics in prevention and care*, 2021

Collet, G., Parodi, N., Cassinari, K., et al., Cost-effectiveness evaluation of pre-counseling telephone interviews before face-to-face genetic counseling in cancer genetics, *Familial cancer* 17, 451-457, 2018

Eccleston, A.B., Anthony, D. M. et al., A Cost-Effectiveness Evaluation of Germline BRCA1 and BRCA2 Testing in UK Women with Ovarian Cancer, *Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research* 20, 567-576, 2017

Hoskins, P., Eccleston, A., Hurry, M., et al., Targeted surgical prevention of epithelial ovarian cancer is cost effective and saves money in BRCA mutation carrying family members of women with epithelial ovarian cancer, *A Canadian model, Gynecologic oncology* 153, 87-91, 2019

Hurry, M., Eccleston, A., Dyer, M., et al., Canadian cost-effectiveness model of BRCA-driven surgical prevention of breast/ovarian cancers compared to treatment if cancer develops, *International journal of technology assessment in health care*, 36, 104-112, 2020

Ovarian cancer: identifying and managing familial and genetic risk, Supplement 2 – Economic literature DRAFT for Consultation (September 2023)

Kwon, J.S., Tinker, A.V., Hanley, G.E., et al., BRCA mutation testing for first-degree relatives of women with high-grade serous ovarian cancer, *Gynecologic oncology*, 152, 459-464, 2019

Kwon, J.S, Tinker, A., Pansegrau, G., et al., Prophylactic salpingectomy and delayed oophorectomy as an alternative for BRCA mutation carriers, *Obstetrics and gynecology* 121, 14-24, 2013

Manchanda, R., Burnell, M., Loggenberg, K., et al., Cluster-randomised non-inferiority trial comparing DVD-assisted and traditional genetic counselling in systematic population testing for BRCA1/2 mutations, *Journal of medical genetics*, 53, 472-80, 2016

Manchanda, R., Legood, R., Antoniou, A.C., et al., Specifying the ovarian cancer risk threshold of 'premenopausal risk-reducing salpingo-oophorectomy' for ovarian cancer prevention: a cost-effectiveness analysis, *Journal of medical genetics*, 53, 591-9, 2016

Manchanda, R., Legood, R., Burnell, M., et al., Cost-effectiveness of population screening for BRCA mutations in Ashkenazi Jewish women compared with family history-based testing, *Journal of the National Cancer Institute*, 107, 380, 2015

Manchanda, R., Legood, R., Pearce, L., et al., Defining the risk threshold for risk reducing salpingo-oophorectomy for ovarian cancer prevention in low risk postmenopausal women, *Gynecologic oncology*, 139, 487-94, 2015

Manchanda, R., Patel, S., Antoniou, A.C., et al., Cost-effectiveness of population based BRCA testing with varying Ashkenazi Jewish ancestry, *American journal of obstetrics and gynecology*, 217, 578e1-578e12, 2017

Michaelson-Cohen, R., Cohen, M.J., Cohen, C., et al., Real World Cost-Effectiveness Analysis of Population Screening for BRCA Variants among Ashkenazi Jews Compared with Family History-Based Strategies, *Cancers*, 14, 2022

Moya-Alarcon, C., Gonzalez-Dominguez, A., Simon, S., et al., Cost-utility analysis of germline BRCA1/2 testing in women with high-grade epithelial ovarian cancer in Spain, *Clinical & translational oncology: official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico*, 21, 1076-1084, 2019

Muller, D., Danner, M., Rhiem, K., et al., Cost-effectiveness of different strategies to prevent breast and ovarian cancer in German women with a BRCA 1 or 2 mutation, *The European journal of health economics, HEPAC: health economics in prevention and care*, 19, 341-353, 2018

Muller, D., Danner, M., Schmutzler, R., et al., Economic modeling of risk-adapted screen-and-treat strategies in women at high risk for breast or ovarian cancer, *The European journal of health economics, HEPAC health economics in prevention and care*, 20, 739-750, 2019

NICE 2013, Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer, *Clinical guideline [CG164]*, Last updated: 20 November 2019

Patel, S., Legood, R., Evans, D.G., et al., Cost effectiveness of population based BRCA1 founder mutation testing in Sephardi Jewish women, *American journal of obstetrics and gynecology*, 218, 431e1-431e12, 2018

Philpott, S., Raikou, M., Manchanda, R., et al., The avoiding late diagnosis of ovarian cancer (ALDO) project; a pilot national surveillance programme for women with pathogenic germline variants in BRCA1 and BRCA2, *Journal of medical genetics*, 2022

Ramos, M., Folgueira, M.A.A.K., Maistro, S., et al., Cost effectiveness of the cancer prevention program for carriers of the BRCA1/2 mutation, *Revista de saude publica* 52, 94, 2018

Schwartz, M.D., Valdimarsdottir, H.B., Peshkin, B.N., et al., Randomized noninferiority trial of telephone versus in-person genetic counseling for hereditary breast and ovarian cancer, *Journal of clinical oncology: official journal of the American Society of Clinical Oncology*, 32, 618-26, 2014

Sun 2023 – in publication

Tutty, E., Petelin, L., McKinley, J., et al., Evaluation of telephone genetic counselling to facilitate germline BRCA1/2 testing in women with high-grade serous ovarian cancer. *European journal of human genetics: EJHG*, 27, 1186-1196, 2019

Yamauchi, H., Nakagawa, C., Kobayashi, M., et al., Cost-effectiveness of surveillance and prevention strategies in BRCA1/2 mutation carriers, *Breast cancer (Tokyo, Japan)*, 25, 141-150, 2018

1